e ,

2013

, , 2013

: . - . ,

ISBN 978-954-9318-26-5

: , .
8; . 0887005092; e-mail: ditcheli@abv.bg

............................................................................................................. 7
. ............................................................ 8
- .................................................................................... 8
.................. 11
............................................................................................. 14
............................... .20
................................................................................................................. 20
............................................................................................... 21
...................................................................................... 24
......................................................................................................................... 27
....................................................................................................... 28
................................................................................................ 29
........................................................................................................................... 32
() ............................................................................ 33
........................................................................................... 37
.................................................................................... 40
...................... 45
......................................................................................................................... 52
..................................... 55
- .................................................................................. 55
............................................................................................ 56
............................................................................................. 58
...................................................................................... 61
.................................................................................................................................... 61
................................................................................. 62
............................................................................................ 64
..................................................................................................... 67
.................................................................................................... 70
......................................................................... 73
........................................................................................ 76
() ................................................................................................................ 76

3
 ( )....................................................................................... 77
...................................................................................... 77
....................................................................................... 78
............................................................................................................... 79
( ) ...................................... 79
( ).................................... 81
...................................................................................................................... 84
...................................................................................... 85
.............................................................................................................. 86
( ) ................................................. 86
........................................................................... 89
- .............................................................................. 91
() ............................................................................. 92
( )................................ 96
.............................................................................................................................. 98
( ) ........................................................ 100
( -) ............................................................. 101
..... 102
....................................................................................................................... 109
................................................................. 112
- .................................... 112
- ................................................................................ 112
................................................................................ 113
.......................................................... 114
......................................................................................................................... 114
.................................................................................................................. 118
......................................................................................................................... 121
....................................................................... 125
- ................................................................................ 125
................................................................... 126
........................................ 127
................................................................................................................... 127
( ) ..................................................................................... 128

4
................................................................................................................. 131
..................................................................................................... 135
..................................................................... 136
- ................................................................................ 136
............................................................... 137
..................................... 137
( -) ................................................. 137
( ) ......................... 140
............................................................ 144
........................................................................................................................... 144
........................................................................................... 146
...................................................................................................................... 147
..................................................................... 156
..................................................................... 161
......................................................................................................................... 164
.................................................................................................................................. 168
..................... 170
....................................................................................................................... 176

()................................................................................................................. 179
............................................................................................ 179
................................................................................ 183
............................................................................................. 185
........................................................................................................... 186
....................................................................................................................... 187
................................................................... 190
.......................................................................................... 190
........................................................................................... 190
............................................................................ 191
- ..................... 192
............................................................................................................. 192
( ) ....................................................... 196
......................................................................................................................... 199
......................................................................................... 203

5
 .......................................................................................................................... 204
................................................................................................... 207
- ............ 208
....................................................................................................................... 210
....................................................................................................... 212
..................................................................... 214
............................................................................... 215
.............................................................................................. 216
.......................................................................... 218
.................................................................................. 219
............................................................................................................ 219
............................................................................................................ 220
.................................................................................................................. 221
............................................................................. 223
........................................................................ 226
....................................................................................................................... 229

-
-
, -
, - . -
,
. -
, , -
-
.

-
- -
, , , -
- , ,
.
.
-
,
. , -
, -
- -
, ,
.

,
(), ().

,
, .
, : 12
., 6 , 3 .
, . , -
. ()
,
.

, -
(cortex), -
, (, medulla), - -
, . -
, ,
,
.

8
 ,
: 1) 2) .
1-1,2 . .

( ) -
-. -
,
, .
, .

().
, -
.

,
, , .
( ),
. -
.

:
( ), ,
(
) . , -
, -
.

, , -

- .

, -
:

1. () .
-
(, , .), ,
.

9
 2. . -
-
-, -, , -
.

3. . -
, -
. ()
, -
. -
, -
. D
.

-
, -
.

1. . ,
,
( -). -
,
. 1010.

2. .
, -
,
. 100% , -
, , 80% , .

3. .
,
, .

1,2-1,5 l/24 h.
- -
, -
.

10


1. (polyuria) 2000
ml/24 h. : ( , -
) -
, , .

2. (oliguria) 500 ml
( 100 500 ml/24 h). -
, , , t
, ,
.

3. (nicturia) . -
. -
3-4:1.
.
, , .

4. (pollakiuria) .
, , , .

5. (disuria) , , -
, , .
-
, .

6. . .
, .

7. (proteinuria)
150 mg/24 h. -
. :

150 mg 0,5 g/ 24 h;
0,5 3,5 g/ 24 h;
3,5 g/ 24 h;
;
() .

11

, , .
()
- 3,5 g/24 h,
; - () -
2 g/24 h.
8. -
, , ,
.
:
2;
--;

( -).
-
, -
. -
2
,
. -
.
( ) -
, ,
.
,
.
, . -

, - .
9. - , :
;
;
.

12
 : - -
, , , -
.

: -
. -
-
() .
(3-5 g/24 h).
()
, (1 g -
20 g ) . -
.

: - -
.
, , , , , - -
.
, .
, , -
. , , -
, . -
, -
( 20-30 g/24 h), () ,
, , -
, .

: , -
. :

, ,
;

,
(, ),
(), , .

-,
.

13


-
, ,
..
,
, ..
, , .,
. -
, ,
. -
, , , , ,
, ,
., ,
.

. -
,
, - -
. ,
, , , , , .

. -
, -
, , .
,
, .
.

(succussio renalis). -
, (-

14
, , .) , -
.

.

. -
- . -
24- .

,
- 24- .
, , ..
1,5 2,0 l 1,2 1,5 l .
3:1 4:1. -
2 l/ 24 h , 0,5 l/ 24 h -
, 100 ml/ 24 h .

()

1 ml .
. -
.

1001
1036, 1015-1025 ( 1035). -
- 1005,
1030.

, -
.,
,
1005 1014.

1010 -
. ,
.

15


. -
;
.

-
. , -
. , , ,
. -
.
, ; ;
.

.
. -
, , , -
. -
, , , .

,
.
.

()
. 4,5 8,0 -
-
; . -
( 6). -
, , , .,
.

16
 ()

. 100 1200 mOsm/kg H2O -
.

1.
, , ..

2. , , ,
, , .

, , ,
, , (.. 6 mg/24 h).

;
: , , . -
5-10 ; ;
; -
, .
. -
, , , , .;

(,
- ). -
, , ,
.
. - -
, , , -
.
.
.
.
, .

17
 3.

, -
() -
.
, ,
, , , , , .
4. ()

. -
.

1. (Folhard) -

. -
.
2.
. -
.
3. -

.
4.
. () -
, ml, -
(1 min).
, , .

1. ()
-
, -
( ).

18
 2. ()
-
-
, , -
.
. -
2-3 ,
,
.

3. ()
- -
, , , . -
, .

4. () -
-
.

()

,
-
. ,
, ,
. -
, , , .
.

()

. -
, , .

,
-
.

1. , -
,

19
 (-131-) .
, .

2. , -
.
, ,
, , ..

,
. -
-
, , .
, -
, , ,
, , .

-
, .
:
, ,
, -
(--, .). -
-
, .

(Glomerulonephrites)

:
.

20
 :
, -
.
3 :

1. -
G M (IgG, IgM)
3- . ,
.

2. - -
.

3. -
-
, -; -
, .

(Glomerulonephritis acuta)

: ,
. ,
, , .

, - .

:
- . -
.

: -
IgG ( G) 3- .

: -
, , . -
, ,
. -
-
.

21
 :
-
10 21 .
- , , , -
, , .

,
, , .

- . -

, 1-2
. , , ,
. -
.

70% . -
140-160/95-120. -


, .
,
1 .

-

.

, .
-
.

500 ml
, .

-
1 , . -
.

3 g/24 h;
, , .

22
 , -
, -
.

-
, , -
(.).

: -

. - ,
, , -
.

: ,
.
.

1. - .
, .
; 1 l -
; , , 1500 kcal/.
-
.

2. 1-2 . 40 mg , -
2-3 . . , -
,
4-5 . 20 mg 250 ml 5%
.

3.
, - .

4.
1,5-3
.; 5 400 mg (2 g/.).

: -

23
 .
.. , -
, , .

(Glomerulonephrites chronicae)

V.

V.

V. IgA

, , , -
-
.

: , -

. -
, -
.

: -
: + +
.

.

24
 ,
, , , , . -
, , -
. ,

. ,
. ,
, , . -
. , -
( 20-30
g/24 h), (.) , -
, , , -
. -
, ,
.

. -
, , -
. .
, -
.
,
.
,
-
.
,
. ,
.
: , -
,
.

: : 1)
; 2) ,
; 3)
; 4) .

25
 . -
,
, ,
, .
.

-
. , -
, .
, -
: , -
.

.

, , ,
, .; . -
, .

,
, ; -,
, ; -
, . -
, .

: -
.

. -
.
. , -
, -
. -
.

26


(Pyelonephrits)

: -
, -
. - -
. , -
, .
, -
, - .
: - .(-) . ,
, , . ,
-
.. L-.
.
-
: ,
(, .).
: (
), (-
), (
) .
:

1. :
( )
.
2. :

/ .
: :

1. -

2. () - (80%). -

27
 () ( ). -
.
,
, .
, -
() ,
.
.

(Pyelonephritis acuta)

:
.
.
, ,
.
.

:
39-400 , , .

, .
, ,
. -
. ,
, . , -
.
. . .

: ( -
), (
), , ,
, . -
.
.

1. ,
;

28
 2.
,

3. .

:
10-15 . -
.

(Pyelonephritis chronica)

: ,
. ,
, .
, . -
. -
. . -
.

: -
, ,
-
.

. -
-
, , , -
, ,
. ,
, . ,
, , -
, .

,
,
, , -
, . -
, -

29
 -
.

-
-
. -
, ,
, -
, +-
. , ,
, . .
, -, , , .
-
. -

. , , -
, , .
-
.

, -
, , . -
, -
. , , -
.

: , -
. -
, , :

(, ,
);
;
;
+ (Hodson) ,
, .
()
- ,
.

30

, .

,
/ 1; -
; .

: , , , .

: ,
.
.

1.

-
.
. ,
. ,
.
, -
, ..
-
, , , , -
, , 1,5-2,0 l.
, , .
-
( 7) , -
, ;
( , , , ,
, , .).
, , , , .

2.

, , -,

-
,

31
 . , -
-
(, , - ,
4- , .).
.
. -
10 20 . -
+ , +
, + .

,
, , 1, 6 .

(Cystitis acuta)

.
- , . -
.

- -
(
), , -
, ( ),
, , -
, , .

: , -
, ,
( ). , , -
, .
, . -
: , -
, .
. .

32
 : - -

.

: , -
;

, , -
, ;

: (-
), ( ); -
( .), 5-; -
(, , ,
.).

. -
.

, ;
( , ,
; .).

(Nephrolithiasis)

-
.
() , -
.

1. ,

, ;

33
 , -
, , ;
, :
, ,
( ); -
( ,
. ); -
, , , .

2.
. ;
.

3.
, ,
.

4. ,
, -

, , , .

. ,
(). - :

, , ;
, , ;
, , -
, ;
.

: -
, .
() .

. -

34
 ,

, .

,
.
, , , -
, . , ,
. -
, ,
, . -

, , . -
.
, , , , . -

-
, . -
. -
.

: -
,
. , -
, , , .

: -
, ,
, -
.
, , -
.

: , -
, .
() -
, -
, . - -
, -

35
, ,
.

, -
, .
, -
, , ., .
, .

-
, . -
:

, -
+ , . -
() , -
, .

, -, , , .

,
-
.
.

2-3 l ,
.

-
.

-
, , -
; -
.

-
, 2 l, -
, , , , ,
. .

36
 -
400-600 mg e. -3 5 . ,
. D
.

-
, -
, ,
.

(
6,4-6,8), , ,
, . , , -
-
, , , , . -.

-
,
, , , . , -
, , , , .

: () -
, -
. (1-7 )
( 24 h) , .
( )
, - -
.

: , ,
, , , -
, , -
.

37
 : , ,
-
, ., (-
), , ,
.

:
, , , ,
.

: :

1. (),
-
. .

2. .
, ,
-
.

3. .

: 4 :

( )

, -
, , , , . -
1-3 , .

-/

-/-
, 500 ml /24 h
( 50-100 ml/24 h).
, , , ,
, , , .
, . ,
, .
, -
, , , ,

38
. ,
. .
, 2-5 ,
.

3-4 , -
10 l/24 h.
, -
, . -
(
) .

3-12 .
6 . -
.

: ,
.
, , ,
.. -
24- , , , -
, , , -
, . -
-,
. -
, 10%.
,
,
(Sorbisterit).
.
. -
, , .
.

-/ -
, , -

39
 .
, ,
, , , . -
7.

: () -
- ,
. 70-
75%
,
. -
.

- -

(). ,
,
, .

: ,
,
, ,
, , .., ,
.

:
, ,
(,
, .).
(, ), (-
) - ( )
.

: (),
5 .

40
 : ( 90
ml/min/1.73 m2);

: ( 60-89
ml/min/1.73 m2);

: ( 30-59
ml/min/1.73 m2) ;

V : ( 15-29
ml/min/1.73 m2) , ;

V : ( 15 ml/min/1.73 m2)
.

: / .
. -
-
, . -

.
,
.
1. , , , , -
.
, , , .
- ,
. , ,

, ,
, , ,
. -
, , -
.
2. , -
( ,
,
.). , -

41
 , , ,
.

3. -
, , , , , . -
-
.

4.
. -
, , , -
.
.

5. - -
,
. -
, .

6. , ,
. , -
.

7.
, -
, . D, , .

8. -
2-3 l/24 h,
-
, .
.
. , -
, , ,
. :
7,30,
20 mmol/l, -2,5 mmol/l.
: -
, ,

42
 , , , -
.

: -
, ,
,
, , .

.
-
, , .
,
-
.

, -
.
1,0 0,35g/kg -
. - 50%
( , , , ), -
. -
,
Aminomix, Aminoplasmal, Aminosteril, Glutarsin, Nephramine. -
60-80 g . -
. ,
3
g . ,
, .

,
, ,
.

, 5%
, 5% .

-
Eprex, Recormon.

-
. (15% 10 ml

43
Kalium chloratum) , . -
-
. 10% 20ml Calcium gluconicum,
, . -
.
-
. -
Rocaltrol (Calciferol).

, -
, -
. -
,
.

, -
, -, , . -
-
, .
40% 10% -
. .

. -
, . -
, .

, .
.

. .

44


1.
(, ) ;

2. ( -
, , ,
..) ;

3. ;

4.
, -
7 7- 7-;

5.
;

6. ,
, -
;

7. , -
(, , , ), ,
, -
;

8.
(, , , ), -
, , ..;

9. ,
, -
, -
;

10.
,

;

45
 11. :

: -
, ( , ), , ,
, , , , , -
;

( , , )
;

()
, , , ;

-
;

12. :
,
;

, ;

-
;

46

, -
;

-
(, , ).

13.
:

: , 100 ml
(, ),
, , , ;

,
, ;

-
;

14. -
:

,
;

, -
..
-
, .;

;
-
- 1 h ;
.

47
 15.
:

-
, -
;

,
, , , -
, , , -
, ,
, ;

, ;

2-3 cm
;

;
-
;

;
;

.
16. -
:
-
, -
;

48
 ,
, , , -
, , , -
, ,
, ;

, ;

, -
;

,
;

-
.

17. -
:

,
;

49
 7-10 ;

,
.

18. :

-
;

, -
-
;

,
, ;

,
, ;

, ;

, -
;

50

;

19. -
:

-
;

-
;

-
;

-
,
, -
2-3 , ;

21.00 h
;

-
12 h ;

-

;

20.
:

-
;

51
 -
, ,
; -
; , -
;

, -
.

1. , . . ., . ., 1988.
2. , . . ., . ., 1992, 589 .
3. . . .- . . , , 1994.
4. , . . , , 2006, 460 .
5. , . (- ). ,
-, 2007, 375 .
6. , . . ., . ., 2002, 813 .
7. . . .. . ., 2008.
8. , . . . ,
, 2009, 296 .
9. , . . . , 2002.
10. , . . . ., , 2005, 106 .
11. . . . . . . . .,
. ., 1987.
12. , . . ., ,
2012, 208 .
13. , . . ., 2002.
14. B o r g h i , L. et al. Comparison of two diets for the prevention of recurrent stones in idiopathic
hypercalciuria. N. Engl. J. Med., 346, 2002, 2, 77-84.
15. B o u l w a r e , L. E. et al . Identification and referral of patients with progressive CKD: a national
study. Am. J. Kidney Dis., 48, 2006, 192.
16. C a m e r o n , J. S. The Long-Term Outcome of Glomerular Diseases. In: Schrier RW, Gottschalk
CW, ed. Diseases of the Kidney. 6th ed. Little, Brown & Company: Boston, Mass; 1997, 1919.
17. C h a n d h o k e , P. S. Evaluation of the recurrent stone former. Urol. Clin. North. Am., 34,
2007, 3, 315-322.
18. C o o p e r , J. T., G. M. Stack et T. P. Cooper. Intensive medical management of ureteral calculi.
Urology, 56, 2000, 4, 575-578.

52
19. Coresh, J., M. Walser et S. Hill. Survival on dialysis among chronic renal failure patients treated
with a supplemented low-protein diet before dialysis. J. Am. Soc. Nephrol., 6, 1995, 5, 1379-
1385.
20. E v a n , A. P. et al. Mechanism of formation of human calcium oxalate renal stones on Randall's
plaque. Anat. Rec. (Hoboken), 290, 2007, 10, 1315-1323.
21. G u p t a , K. et al. International clinical practice guidelines for the treatment of acute
uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases
Society of America and the European Society for Microbiology and Infectious Diseases. Clin.
Infect. Dis., 52, 2011, 5, 103-120.
22. J a f a r , T. H. et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic
renal disease. Kidney Int., 60, 2001, 1131-1140.
23. K a w a s a k i , Y. Mechanism of onset and exacerbation of chronic glomerulonephritis and its
treatment. Pediatr Int., 53, 2011, 6, 795-806.
24. K / D O Q I clinical practice guidelines for chronic kidney disease: evaluation, classification, and
stratification. Am. J. Kidney Dis., 39, 2002, (2 Suppl. 1), 1-266.
25. K u y p e r s , D. Skin problems in chronic kidney disease. Nat. Clin. Pract. Nephrol., 2009, 5,
157-170.
26. L e z i n , St. M., R. Hofmann et M. L. Stoller. Pyonephrosis: diagnosis and treatment. Br. J.
Urol., 70, 1992, 4, 360-363.
27. L e v y M. et J. Berger. Worldwide perspective of IgA nephropathy. Am. J. Kidney Dis., 12,
1988, 5, 340-347.
28. L u o , C. et al. Clinicopathological features and prognosis of Chinese patients with acute post-
streptococcal glomerulonephritis. Nephrology (Carlton), 15, 2010, 6, 625-631.
29. M a n g r u m , A. J. et G. L. Bakris. Angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers in chronic renal disease: safety issues. Semin. Nephrol., 24, 2004, 2, 168-
175.
30. N a s r , S. H. et al. Postinfectious glomerulonephritis in the elderly. J. Am. Soc. Nephrol., 22,
2011, 1, 187-195.
31. N i c o l l e , L. et al. Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in
young women with acute uncomplicated pyelonephritis. Int. J. Antimicrob Agents. 31, 2008,
3, 287-289.
32. P e t e r s o n , J. et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for
five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated
urinary tract infections and acute pyelonephritis. Urology, 71, 2008, 1, 17-22.
33. P e t e r s o n , J. C. et al. Blood pressure control, proteinuria, and the progression of renal disease.
The Modification of Diet in Renal Disease Study. Ann. Intern. Med., 123, 1995, 10, 754-762.
34. P o l e n a k o v i c , M. et L. Grcevska. Survival rate of patients with glomerulonephritis. Acta
Med. Croatica, 46, 1992, 1, 15-20.
35. P r e m i n g e r , G. M. et al. 2007 guideline for the management of ureteral calculi. Urology,
178, 2007, 6, 2418-2434.
36. R e m u z z i , G., T. Bertani. Pathophysiology of progressive nephropathies. N. Engl. J. Med.,
339, 1998, 20, 1448-1456.

53
37. R e m u z z i , G., C. Chiurchiu et P. Ruggenenti. Proteinuria predicting outcome in renal disease:
nondiabetic nephropathies (REIN). Kidney Int., 92, 2004, 90-96.
38. S e t h i , S., C. M. Nester et R. J. Smith. Membranoproliferative glomerulonephritis and C3
glomerulopathy: resolving the confusion. Kidney Int., 2011.
39. T a l a n , D. A. et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole
(14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA, 283,
2000, 12, 1583-1590.
40. V o u l o u m a n o u , E. K. et al. Early switch to oral versus intravenous antimicrobial treatment for
hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled
trials. Curr. Med. Res. Opin., 24, 2008, 12, 3423-3434.
41. W e n , C..C. et S. Y. Nakada. Treatment selection and outcomes: renal calculi. Urol. Clin.
North. Am., 34, 2007, 3, 409-419.
42. W o l f , G. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary
glomerulonephritis. Nat. Clin. Pract. Nephrol., 4, 2008, 9, 474-475.
43. W o l f , G. et E. Ritz. Combination therapy with ACE inhibitors and angiotensin II receptor
blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney
Int., 67, 2005, 799-812.

54


-
. , (-
) .

.
, , ,
.
, -
,
() ,
.

, ()
.
:
, -
,
(, ),
. -
- , -
-
. -
, .
(),
, -
, , , , ,
(- -).
, -
.

120 -
, 6-7 10-12 .

55
,
.. - (),
.
, .

1.

-
.
. -
,
, , , -
, -
, .

2. -

, , , -
.

56
 3.
,
38-390 -
. ( -
) .. (febris undulans) -
, 1-2 .
- -
.

4.
.
-
, ,
, , ..

5.

, , ,
.
.

6.
, , -
. ,
100-120 mmol/l, -
.

7.
- , ,
-
.
,
().
.

8.
-
.

57
 (), (),
, (),
- (, , ),
(), ,
, .
, (),
, - .

, -
-
. -
,
, , , ,
, .
-
, , , .. -

, . -
,
(,
.) .

-
. -
, , ,
, , ,
.
,

, -
, , , . -
-

58
, -
. -
.

-
. -
(), (Hb), -
(Er), (Leu), (Thr), (Rt), -
(),
(St) (Sg)
, (Eo), (Ba), (Mo)
(Ly). -
(), (V),
(),
. , -
, INR, , .

-
, ,
(), - (), -
(), , ;
- () .

-
, -
(HLA -
). -
IgA, IgM, IgG .

-
, ( ),

, , .

59


, -
, .

()

, -
,
.

, (, -
) , .

-
, -
( , , -
, ..), -
.

-
. -

. ,
, ,
. -
-
, , .

(, , -
) ,

60
, -
. -
, .
,
.

. , 90% -
22,
9
.. .

V.

V.

(Anaemiae)

: ,
, ,
. , -
130 g/l 120 g/l .

61
 :

. , ,
:

1. , -
, .

2.

3. -

. ,
, .

(Anaemia posthaemorrhagica acuta)

: ,
.

:
, , -
, , -
(), .

:
, -
. -
,
(, , -
, ) , , .
-
, -
. -
- ,
, .

62
 :
, . 500-1000 ml -
-, ,
, -
.

( 30% -
1000-1500 ml) (-
) , , ,
, , -
, , , ,
, , , . -
.

40% ( 2000-
2500 ml) -
, , .

: -
. 48 h,

,
. , -
-
. ,
. -
( , -
) .

-
15-30 , -
2 .

: -
.
:

1.
. 10-20 ml

63
10% 500-1000 mg, 1-2 .
, 5 ml 6-8 h .

2.
- (Ringer, Hartman), , 5% Serum
glucosae, , , -
. , -
() . -
.

3. - ,
.

-
.

(Anaemia ferripriva, Anaemia sideropriva)

: , -
. -
.

1. , , , -
, .
-
.

2.
, , .
,
.

64
 3. , -
, (),
.

4.

-
.

: -
(.. -
). , . -
,
.
,
2 -
.
.

1. ;

2.
, , .;

3. -
, , , ;

4. ,

: .
,
: , , , -
, , , ,
, . -
-
. , -
,
. ,
, . -

65
 , , .
, , (), -
, , , ,
(). ,
, .
, , . -
,
, .

: -
, , ,
(V).
, , , .
.
, -
().

, ,
(, .).

: ,
.
, ; -
.

, -
, (, , . , -
.).

Ferrum Hausmann, amp.

2 5 ml i.m., Maltofer, Venofer i.v., 20

Glubifer, Ferro-gradumet, Polyfer,

Hemofer, Ferronat, Vitaferro . 1 . , -
25-30 .

-
, 6-9 . 10- -
. - - 1 ./.

66
 -
.

(,
, , ) 1-2- . -
. , , .

( Addison-Biermer)

(Anaemia perniciosa, Morbus Addison-Biermer)

, -
. 12 , -
.

, , -
. 12 .

: .

: -
,
. 12
(. 12 ). -
2
-
( ), .. -
( , )
. 2
. 12 ,
. 12- .
(
) (-
). . 12, -
, ,

67
 -
.
( mega , cyto -
, ), ,
.

, - -
.

: -
. 12 .

: , .
, -
, , , -
. .. ,
3 :

1.
, , -
, , ,
;
, ,
, , ; -
, , ; ,
.

2. -

, , ():
,
, , ,
, ;
() -
.. , -
, , .

68
 3.
. 12
:
,
, , ,
;
-
, , , , -
. , ,
.

: -
. -
(), , -
(). ,
-
. .
.
-
. , ,
.
, .

: ,
. -

, -
, . -
. 12 .

: . 12.
.
12 ().
. 12 1000 mcg/. 15-20 . -
,
3-5 . -
20 mg/. 24 48

69
 . 12 -
.
:
. 10 . 12
1000 mcg/., 15 , 1
2-3 . 1 . (500 1000 mcg).
. , . 6, 1, ,
, .

- (Hildicon) 1 .
1000 mcg 75-100 .

, 4-6
.

,
() -
(), -
-
.

() -
(). -
, -
, , -
. -
() , ,
- -
, ( -
), ,
.

. (), -
:

70
 1. -
-
, .;

2.
, .;

3. -
.

. , :

1. ;

2. () .

(Anaemia haemolytica congenita microspherocytosa

Minkovsky-Chauffard)

- .
- .
. .

: -
,
() .

: -
.
. -
-
. ()
,
- .

:
, - 4 10 .
:

71
 -
. ,
, , .

,
. .

,
, , -
. ,
.

, , ,
.

: -
, ( -
, ), -
, . -
.
,
, , .

:
, -
; .

:
. (Urbason),
, .

- . -
10- .
,
,
.

: ,
.

72
 , -
, -
Rh-, ,
, , -
( , , , ,
, .); ,
(, .) .

.
, -
.
-
. -
, , , -
.
, -
.

(Anaemia aplastica)

: -
, -
, ,
. ,

. -
,
.

: - :

1. , -
, , ;

73
 2. , -
, ,
(, .), (), (-
, , .);

3. , -
, .;

4. ;

5. -
;

6. .

- , -
, :

1. -
;

2.
.

: -
, -
. - -
, -
, ,
. -
-
, , , , , , -
.

, - , ,
, , .
, . -
39-40. -
,
. -
, , , , -

74
 , ,
, .

, -
-
.

: -
. -
2.1012/l.
3.109/l.
50.109/l.
.
.
. -
.
( ), -
.

: -
. - -
,
. . -
, .

: , -
, ,
, -
.

1. , -
, ,
..;

2. -
. ;

3. 500-1000 mg;

75
 4. , -

5. . ,

6. , 25 mg i.m.,
, .

7.
( ) , -
, , , , ; 4- -
, , , .

8. . , , . ,

9. .

10. , -
, .

:
, ,
(,
, , , ..), -

, , , -
, .

()

(Leukemiae, Leucosis)

-
. ()
.
, ,
. -
-
.

76
 :
1. ,
, ,
.
2. .

( )

(Leukemiae acutae)

, -
, , -
.

: . -
,
, (.
70-80 -); -
; ; .. ; -
, -
; -
; -
.

(Leucosis lymphoblasticae acute)

: -
-
.

, ,
, ,
.

, - -
.

: ,
. , -

77
, - . -
. , .

:
. -
( ) - -
. . -
.

:
. -
.

(Leucosis myeloblasticae acute)

: ,
-
(- , , , -
, ). -
.

:
-
. -
; -
; -

.

: -
, - . -
, , - ,
, , . -
, ,
, . -
, , , , -
- , -
.
, , - , ..
.

78
 , -
, ,
, .
.

: , .
-
( 100-200.109/l). -
90-99% ,
, ; (-
) (, -
, , , ..) -
- -
.

,
, ,
. :

, 6-, 6-, ,
(Cytarabine).
(-
); , ,
.
, , -
.

( Myeloleucosis chronica)

: ()
, -
. -
, -

79
 ,
, , .
.

: ; -
.

: ,
.. (-
9 22 ; -
2 -alb c-cis). , -
- , -
, -
, - , , ,
-
. , , -
.
.
-
90% -
.

: -
, , , .
, , -
, (
), , , -
.

, -
. -
(). ,
, -
.
.

-
, ,
, , - .

80
 (10-15.109/l
300-400.109/l);
, , -
. -
,
, .
, -
. . -
,
.

-
( : 10-12 : 1,
3-4 : 1) .
.

: -
,
, -
. (Myleran,
Myelosan); , 6-, -
(Imatinib, Dasatinib, Nilotinib) , -
; ; -
.

: ,
.
(, ,
.), . -

. 3-4 .

( Lympholeucosis chronica)

: ()
,
- - -,
.

81
 , -
(
). , -
, - . -
( )
,
(
, ).

- .
90% - (- ).
- . -
50- .

1. ;

2. ;

3. . -
-, , .

, -
.

:
( ) - -
. ,
, , . - , -
-
. ,
. .
, .

: , -
, , ,
, .

(
, , ) -

82
, , , , -
, .

3-4 cm , -
, . -
.

,
, -
, . -
, -
, -
. ,
.. .

20-30.109/l ,
500.109/l, .
, 50-70%, 90-95% -
.

,

.

, 50% .

: , -
,
. :

(, ) ;

, . ;

-
.

83
 -
, -
.

:
. , -
10-15 . --
, 1-2 .

(Agranulocytosis)

: , -

.

: -
. ( ), -
(, ,
.), ( .),
, (, , -
, , .), .

: ( ,
)
, , , 39-400,
, . 1-2
, , -
, , - -
.
. -
. , ,
.

: -
2.109/l,
,
15% ( 50-70%). -

84
 . .
.
- ,
, ,
.

1. , -
, ,
..;

2. ;

3. 500-1000 mg;

4. , -

5. . ,

6. , 25 mg i.m.,
, .

7.
( ) , -
, , , , ; 4- -
, , , .

8. (Leukogen), -4
(Leuko-4).

9. , -
, .

: ,
.
. -
- (--).

85
 - -
, . -
-
, (IgG, IgA, IgM .).

-
() ,
- -
(, .). -
-
-, - -. -
, .

- -
. -
.

.. ,
.

( )

(Morbus Hodgkin)

-
. - .

: . - -
, HIV , -
. , -
, -
-.
, .
.

86
 : ,
-

. -
- -
. -
,
, - .
-
. Reed-Sternberg (R-S- -
).

: -
(). - -
.
. ,
, , .
.
, .

(), .
, , ,
380 , , , -
. ,
. -

, , ,
(v.cava superior-). -
- , -
, . -
.

4 :
. 1 ;
. 2 ,
;
. ,

87
 V . ,
.
,
380; -
10% 6 .; .

; , -
; -
. .
,
,
, R-S-
( ).

: . -
, -
. :

- ,
, ,
, , , .

-
. - :

Mustargen (Nitrogen
mustard), Vincristin (Oncovin), Procarbasine (Natulan), Prednisone.

COPP Ciclophosphamid

V . ABVD Adriamycin,
Bleomycin, Vinblastin, Dacarbasine.

, Bleomycin,
Etoposide, Doxorubicin, Ciclophosphamid, Vincristine, Procarbasine,
Prednisone (BEACOPP).

6 2 .

- 80-90%
.

88


()
. -
20- 40- .

: , -
. -
- - , -
-. 90% -, 10% -.

: -
,
( -). -
. , , -
,
- , -
-
.

,
.

: ,
.
, , , , ,
, , .

: - -
, , , -
. ,
, . -
, , -
. -
, , .
,
. -
.

89
 -
/ , -
.

-
.

.
. -
; . -
.

: . -
1 cm, -
-
, .

1. , -
, ;

2. -
, -;

3. ;

4. -
. .

: :

, ,
/ 2 (
30 mm, . 1010 g/l; . 1,5 g/l, 110 g/l ).

( ) .

4 cm ; 4 cm +

90
 4 cm ; -
4 cm + 4 cm .

: ,
,
.

(, ) -
.

, , -
: V (, -
, ), (, , ,
).

(Ig)
. ,
-, -
.

, 2 2 ,
. 5
IgG, Ig, Ig, IgD Ig, 5 .
() () .
, .

,
() (V). -
, -
. ,
.

- IgG 2/3
. . IgG -
, , -
.

91
 Ig 2 . Ig
. Ig
, , , -
, , - . ()
.

Ig
. , ,
.

Ig . -
, .

IgD .

- -
, -
, -
. -
, .

(, -Kahler)

(Myeloma multiplex, Plasmocytoma)

: ,

(-),
, .
,
. ( ).

, .
, 60-70 .

: -
, , , -
, .

92
 , -
.
6 .

-
. -
,
.
- (),
-
, , .

( ).
, , -
. -
.

60% IgG , 25%

Ig . 2/3 IgG
. 20% -
-
Bence-Jones. , -
.
,
.

: -
.
-
, ,
.

: -
,
, .

- , ,
, . (

93
 , ) -
. (,
, , )
mm cm.

,
, .
. -
, , -.

( )

(, ). -
, , , . -
-
( Bence-Jones). .

, , , , -
, -
.

,
, , ,
. -
.
, ,
.

, .
, -
.

-
,
, , .

: -
, .

94

.

, ,
. .

, ,
.. -
; ; ,
20%; (
). ,
Bence-Jones , -
.
, , ; ; -
Bence-Jones.

-
- IgG, Ig, Ig, IgD , -
. .

-
15-20%, -
, ; -
.

:
. -
:

,
.

, -
, , .

-
.

,
.

95
 -
-, , -
.

.
, -
.

. -
,
,
2 l . .

( )

, -
. -
, .

13 : -
; ; ; V ;
V ; V ; V ; V -
; ; -
-; ; ;
.

() -
. -
, -
.

()
, ..
.

96
 ( ) -
,
, (..
), .

-
, ();

V 60 min -
180 min.
, () .

V , -
,
.

-
, .
(
) ,
( ) -
.

. -
.;

. -
( , .), -
( .);

. ,
(
- .).

97
 (Haemophilia)

: ,
- -.

, ,
2 -.

:
. -
V .
V ,
, (
). - .

.
-
.

1% -;

- 1 5%;

6 30%.

: .
, -
, -
, .

. , ()
. -
, , ,
. -
-
.

()
, , , . -

98
 ,
. ,
.
, ,
.

-
, .

-
- , ; , .

,
.

: -
. -
,
. V .

: -
. -
-
.

( , )
-
1 amp. i.v. , 3
1 amp./. i.v.

-
! !

, -
, ,
.

: .
, -
-
,
.

99
 ( )

(Thrombocytopenia essentialis, Morbus Werlhof)

- .
.

: -

- .
- IgG .
-1 h 7-10 .

: .

, - 1-4 -
. ,
-
, . -
, ( -
) . ,
, . -
.

.
, , -
, -
. , -
, , -
, , ,
. .

: , -
, , ,
, IgG . -
.

: (), -
(, ), , (-
, ), (, .). -
.

100
 ( -)

(Capillarotoxicosis, Morbus Shonlein-Henoch)

- . -
- .

: -
, . -
,
. ,

.

: , ,
, ( ) -
. -
, . -
,
, . -
- 1-2
.

-
, , -
.

, -
.

, -
.

3-4 .

: ,
(, , .) ,
, ,
(, .), -
.

101


1.
(, ) ;

2. ( -
, , ,
..) ;

3. ;

4.
, ;

5.
;

6. , -
;

7. , -
(, , , ), ,
, -
;

8.
(, , .), , -
, , ,
, ..;

9. , -
, . , -
,
;

10.
,
;

102
 11. -
:

: -
, ( , ), , ,
, , , , , -
;

( , , )
;

()
, , , ;

-
;

12. -
:

,
;

, , -
;

2-3 -
, , ,
( 2-3 , , , ,
, , ,

103
 , ), ,
10 , (, ,
), ;

, ;

,
, ;

3-4
: , , -
, , ..

, ,
;

24 h;

13. -
:

-
RH- -

104
 , , , -
, , -,
, 2 . ,
2 .,
;

-

RH- ;

, -
;

3
;

-
;

14. -
:

,
;

-
, -
, , , ,
;

, -
;

, -

105
 , , -
, , , ..;

30-40 /min.

,
, , , , -
;

24 h : ,
, ;

( -
, , ) -
, -
, , -
1 min, -
;

15. -
, -
( , .).

16.
:

-
;

, -
; ;

, -
.

106
 17.
(, , , ):
-
;
;

;
-
;
.
18. -

:

;
;

( , ,
.);
-
;
.
19.
:

;
;
-
;

( , ,
.);

107

;

20.
:

( , .);

, , , ,
RH ; ,
;

();

21. -
:

( , .);

-
;

108


1. , . . ., . ., 1992, 589 .
2. . . . - . . , , 1994.
3. , . . , , 2006, 460 .
4. , . (- ). ,
-, 2007, 375 .
5. , . . ., . ., 2002, 813 .
6. . . . . . ., 2008.
7. , . . . , -
, 2009, 296 .
8. , . . . ., 2002.
9. , . . . ., , 2005, 106 .
10. , . . ., 2002.
11. A l l e y n e , M., M. K. Horne, J. L. Miller. Individualized treatment for iron-deficiency anemia in
adults. Am. J. Med ., 121, 2008, 943-948.
12. B a c c a r a n i , M., J. Cortes, F. Pane et al. Chronic myeloid leukemia: An update of concepts and
management recommendations of the European LeukemiaNet. J. Clin. Oncol., 27, 2009, 6041-
6051.
13. B a c c a r a n i , M., G. Saglio, J. M. Goldman et al. Evolving concepts in the management of
chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European
Leukemia Net. Blood., 108, 2006, 1809-1820.
14. B a c i g a l u p o , A., J. Passweg. Diagnosis and treatment of acquired aplastic anemia. Hematol.
Oncol. Clin. North. Am., 23, 2009, 2, 159-170.
15. B o l t o n - M a g g s , P. H. et K. J. Pasi . Haemophilias A and B. Lancet, 361, 2003, 9371,
1801-1809.
16. B r i t t e n h a m , G. M. Disorders of iron metabolism: Iron deficiency and iron overload. In:
Hoffman R, et al. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa.
Churchill Livingstone Elsevier, 2009.
17. B r u s a m o l i n o , E., A. Bacigalupo, G. Barosi et al. Classical Hodgkins lymphoma in adults:
Guidelines of the Italian Society of Hematology, the Italian Society of Experimental
Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up,
management, and follow-up. Haematologica, 94, 2009, 550-565.
18. C i n e s , D. B. et V. S. Blanchette. Immune thrombocytopenic purpura. N. Engl. J. Med., 346,
2002, 995-1008.
19. C l a v i e z , A. Hodgkin-Lymphom. Interdisziplinre Leitlinie der Deutschen Krebsgesellschaft
und der Deutschen Gesellschaft fr Pdiatrische Onkologie und Hmatologie. 2007.
20. C o r t e s , J. E., D. Jones, S. O'Brien et al. Results of dasatinib therapy in patients with early
chronic-phase chronic myeloid leukemia. J. Clin. Oncol., 28, 2010, 3, 398-404.
21. D r f f e l , W. et G. Schellong. Morbus Hodgkin. In: Gadner H, Gaedicke G, Niemeyer CH,
Ritter J. Pdiatrische Hmatologie und Onkologie Springer-Verlag, 2006, 752.
22. F l i n t , A., N. B. Kumar et B. Naylor. Pulmonary Hodgkins disease. Diagnosis by fine needle
aspiration. Acta Cytol., 32, 1988, 221-225.
23. F r a n c h i n i , M., G. Gandini, T. Di Paolantonio et al. Acquired hemophilia A: a concise review.
Am. J. Hematol., 80, 2005, 1, 55-63.
24. F r e d e r i k s e n , H. et K. Schmidt. The incidence of idiopathic thrombocytopenic purpura in
adults increases with age. Blood, 94, 1999, 3, 909-913.

109
25. H a n s e c l e v e r D. t A.Diehlv. A prognostic score for advanced Hodgkins disease.
International Prognostic Factor Project on advanced Hodgkins. N. Engl. J. Med., 339, 1998,
1506-1514.
26. H i l l m a n , R. S. et al. Iron-deficiency anemia. In RS Hillman et al., eds., Hematology in
Clinical Practice, 5th ed., 2011, pp. 53-64. New York: McGraw-Hill.
27. H u w e , J. Autoantikrper bei Hodgkin-Lymphom-Patienten mit und ohne begleitende
Paraneoplastische Neurologische Syndrome.Inauguraldissertation. Gieen 2009, 69.
28. I r o n - d e f i c i e n c y anemia. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.
gov/health/dci/Diseases/ida/ida_all.html. Accessed Jan. 24, 2011.
29. I r o n - d e f i c i e n c y anemia. American Society of Hematology.
http://www.hematology.org/Patients/ Blood-Disorders/Anemia/5263.aspx. Accessed Jan. 24,
2011.
30. K a n t a r j i a n , H., N. P. Shah, A. Hochhaus et al. Dasatinib versus imatinib in newly diagnosed
chronic-phase chronic myeloid leukemia. N. Engl. J. Med., 362, 2010, 24, 2260-2270.
31. K a n t a r j i a n , H. M. et M.Talpaz. Chronic myelogenous leukemia. Hematol. Oncol. Clin. N.
Am., 18, 2004, 3, 15-16.
32. K a n t a r j i a n , H. M., A. Hochhaus, G. Saglio et al. Nilotinib versus imatinib for the treatment
of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic
myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Lancet Oncol., 12, 2011, 9,841-851.
33. K a n t a r j i a n , H. M., J. E. Cortes, S. O'Brien et al. Imatinib mesylate therapy in newly
diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high
incidence of early complete and major cytogenetic responses. Blood. J., 101, 2003, 1, 97-
100.
34. K a s u g a n t i , D., D. Cimbaluk, P. Gattuso. Reed-Sternberg cells in bronchial brushings from a
patient with Hodgkins disease. Diagn. Cytopathol., 34, 2006, 850-851.
35. K u m a r , R., H. Sidhu, R. Mistry, T.Shet . Primary pulmonary Hodgkins lymphoma: A rare
pitfall in transthoracic fine needle aspiration cytology. Diagn. Cytopathol., 36, 2008, 666-669.
36. L o w e n b e r g , B., T. Pabst, E. Vellenga et al. Cytarabine dose for acute myeloid leukemia. N.
Engl. J. Med., 364, 2011, 1027-1036.
37. M a r s h , J. C., S. E. Ball, J. Cavenagh et al. Guidelines for the diagnosis and management of
aplastic anaemia. Br. J. Haematol., 147, 2009, 1, 43-70.
38. M a u z - K r h o l z , C., S. Gorde-Grosjean, D .Hasenclever et al. Resection alone in 58 children
with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European
network group on pediatric Hodgkin lymphoma. Cancer, 110, 2007, 179.
39. N o l a n , B., V. Vidler, A. Vora et al. Unsuspected haemophilia in children with a single swollen
joint. BMJ, 326, 2003, 7381, 151-152.
40. P r o v a n , D., R. Stasi, A. Newland et al. International consensus report on the investigation and
management of primary immune thrombocytopenia. Blood, 115, 2010, 168-186.
41. R a d i n , A. I. Primary pulmonary Hodgkins disease. Cancer, 65, 1990, 550-563.
42. R o b e r t s , H. R., D. M. Monroe, G. C. White. The use of recombinant factor VIIa in the
treatment of bleeding disorders. Blood, 104, 2004, 13, 3858-3864.
43. R o d e g h i e r o , F. et al. Standardization of terminology, definitions and outcome criteria in
immune thrombocytopenic purpura of adults and children: report from an international working
group. Blood, 113, 2009, 2386-2393.
44. S a g l i o , G., D. W. Kim, S. Issaragrisil et al. Nilotinib versus imatinib for newly diagnosed
chronic myeloid leukemia. N. Engl. J. Med., 362, 2010, 24, 2251-2259.
45. S a n t o s , F. P., H. Kantarjian, C. Fava et al. Clinical impact of dose reductions and interruptions
of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br.
J. Haematol., 150, 2001, 3, 303-312.

110
46. S a w y e r s , C. L. Chronic myeloid leukemia. N. Engl. J. Med., 340, 1999, 17, 1330-1340.
47. S a w y e r s , C. L. Even better kinase inhibitors for chronic myeloid leukemia. N. Engl. J. Med.,
362, 2010, 24, 2314-2315.
48. S t e i d l C., T. Lee, S. Shah et al. Tumor-associated macrophages and survial in classic
Hodgkin`s lymphoma. N. Engl. J. Med., 362, 2010, 875-885.
49. T a c h i l , J. Thrombotic Thrombocitopenic purpura: is there more than ADAMTS-13? J.
Thromb. Haemost., 2007, 5, 634-635.
50. T a k a m a t s u , H., H. Yagasaki, Y. Takahashi et al. Aplastic anemia successfully treated with
rituximab: The possible role of aplastic anemia-associated autoantibodies as a marker for
response. Eur. J. Haematol., 86, 2011, 6, 541-545.
51. T h o m a s , R. K., D. Re, J. Wolf, V. Diehl. Part I: Hodgkin's lymphoma molecularbiology of
Hodgkin and Reed-Sternberg cells. Lancet Oncol., 2004, 5, 11-18.
52. T i s d a l e , J. F., D. E. Dunn, N. Geller et al. High-dose cyclophosphamide in severe aplastic
anaemia: a randomised trial. Lancet, 356, 2000, 1554-1559.
53. T s a n g , R. W., D.C. Hodgson, M. Crump. Hodgkin's lymphoma. Curr. Probl. Cancer, 30,
2006, 3, 107-158.
54. T u r n e r , M. L., O. M. Boland, A. C. Parker, D. J. Ewing. Subclinical autonomic dysfunction in
patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br. J. Haematol., 84, 1993, 623-
626.
55. W i l d e , J. T. HIV and HCV coinfection in haemophilia. Haemophilia, 10, 2004, 1, 1-8.

111


,
.
, , -
.
, .
, , , , -
, , -
( ) .

: , , , ,
.
, -
.

-
(feed-back) -
. (
, , ) -
- (, , , ).

.
()
() .

(glandula pituitaria) ,
(sella turcica). -
diaphragma sellae. ,
infundibulum, -
.

112
 , 8-10 mm, 12-
15 mm 5-6 mm. 0,6 g,
, -
. : (-
) ().
:
1. () (, )
.
2. () (, )
.
3. ()
.
4. (): () -
()
.
5. ()
.
6. - () -
.
:
1. (, ) -
.
.
2. .

113

, -
- . -
, -
. -
.

-
, .

1. -
, , -
, .

2. .

3. () -
() .

4. .

5. , ,
, , , .

6.
, , , , , -
.

(Acromegalia)

: , -
() (, ) .

. -

114
 , ,
(acron ; megal ).

, -
,
, -
.

- 30-40- ,
.

:
: () -

. -
,
-
. ,
.

: -
. ,
()
, .. -
.

: -
. , -
.

115
 : -
, ,
, .
: ,
.

, , , .
. ,
. ,
cutis gurata. , -
(). .
. , ,
, . ,
, , ; .
.

,
. ,
. - , , . -
() , protuberancia occipitalis externa
. , . -
- -
. ,
. .

116


, , . -
. -
- , -
, , -
. - -
. , -
.
.

,
, .
-
, , ,
.

.
-
, ,
() . -
, -
.

-
, .

: , -
; . -
. -
.

: ;

, , -
(, ), -.

117

(Parlodel) . . . (2,5 mg) .
, .
10-60 mg/.; (Dostinex) -1 . 2 -
/. - - -
; , , -
.

(Diabetes insipidus)

: ( , ) -
, -
(, ) . -
, , -
, .

: -
-
, ( , ,
.), , , -
, - ..
.

: 24
180 l .
85% , -
.
15%
.

, .
, -
. -
24 1,5 l .

118
 . -
280 295 mosm/l. -
280 mosm/l -
. 295
mosm/l .

-

. -
. -
.

1. (, , -
-)
. - . : -
() 1/3
; () 2/3 . -
.

2. (, , -
-). -
.

:
. :

1. ,
. 4 20 l (
1,5 l). - ,
, ( 1001 1005).
285 mosm/l, -
200 mosm/l.

2. .
, . ,
(). -
.
.
, / -

119
 , ,
, , , .

.

, , .

. 2 l/
, 1001-1005
1014 (
). ,
. 300 mosm/l (
200 mosm/l).

: -
.
, , -
/ 2-8 12 ) -
. -
. -
. , - .

: -
, :
( 1025, -
, ); -
, . :
( )
( ); -
.

1.
. -
, , ,
, , -
- .

120
 2. -
, . -
.

3. -
:
(Adiuretin SD), (Desmopressine), (Minirin) 2-8
(10-40 mcg) 12 h .

4.
(Chlorpropamide) 1-2 ; (Carbamasepine)
2-3 1 ./.

5. (Dehydratin Neo) 2-4

./. (. 25 mg) -

(Prolactinoma)

,
, , , ( -
), .

,
, , , ,
, , , .

, -
, , , , , - ,
2- , , , -
.

-
, , , -

121
, . ,
.

1. ;

2. ;

3. ;

4. ;

5. (- );

6. .

: - -
. 50% .
65% .
- () -
.
20-40 ,
- 40-60 . -
- (85%). -
20-30% ,
. -
, .

:
. , -
. ,
, ,
.

1. - , -
. , , -
, ;
. - , ,

122
 . -
- .
, -

.
2. -
. -
.
( , -
). -
.
, ,
.

-- .

.
( -
), ,
.

-
70-80%.
3. -
, . -
.
4.
, , ,
, .
!
5.
.

. -
.
.. -
.

123

50-100%,
. -
.

- .

, -
.
.

()
, (-
,
), .

-
.

,
. -
( -
), , -
, .

, , -
.
.

: , -
; -
, , ; -
, , .

: 2,5 10 mg .; ;
() 0,3-0,6 mg . (1-2 .)

124
 -
, -
.

(glandula thyreoidea) -
, ()
.
30 g. (), -
. -
, .

(3)
(4), . -
( ), , -
, -
.

-
(feed-back)
. -
, -
. 3 4 -
. -

125

.

1. -
, , .;

2. ;

3. ;

4. ;

5. ;

6. -, ,
.

1. (-
, )
;

2. -
(131) ;

3. -
(3 4) ;

4. ;

5. , -
, , ,
, ,
..;

6. -
(, .) .

126


(Struma endemica)

:
(struma).
, . -
, , (-
).

:
(, ) -
.

: -
.

. .

: , (-
) . (struma diffusa)
, , ( , struma
nodosa) .

: -
. -
( ):

0 .
;

. ;

. , ;

. , ;

. ;

. 4-5 m.
.

127
 . -
,
, -
. -
-
. -
.

: .
L- () 100 mcg . 6 .
50% .
, .

: -
(32 mcg/kg 100-200 mcg
). (
100) . 0,5 mg 1 mg -
, , .

(Thyreotoxicosis)

(, )

(Hyperthyroidismus, Morbus Bazedowi)

: ( ) ,
, -
. - 30-50 . -
,
.

128
 : -
, HLA DR3 B8
(HLA human
leucocyte antigen system , -
, , ).

;
, ,
.

: (TSAB
thyreoid stimulating antibodies), -
. -
- . -
3 4

.

:
.
- -
.
.

: - , -
.
. .

, -
. ,
. , ,
. .
, 1, 2 3 , -
.

1. . -
(), -
,

129
 .
.

2. -
- , ,
, (
50% ). ,
. . -
, -
.
, . , -
, , .
3.
/
, /.
4. -
- .
. .
5. - ,
. . -
; - . -
(cor thyreoto-
xicum) ,
.
6. , -
.
7. - ,
.
8. . -
: - , ,
, ,
.

130
 : ,
. -
, ,
.
39-400 , -
, , ,
, 180 ./min,
, , .
,
.

:
, 3 4,
( ); 131 .

: ,
, -
..

: -
: (Propicyl),
(Metizol, Methimazol), (Tapazol), (Tyrozol).
,
. - (),
. , , ,
. -
.

40-60% .

(Hypothyreoidismus)

:
. -

131

4, 3.

4 - . - -
50 .

: -
;
; .

- :

-
;

-
() () ;

131 ,
, ;

; -
, .

:
.

131 -
, .

(3 4)
.

-
. -

.

132
 :

, 3 4 -
, , -
.
, 131 .

, , -
, (50-80%) ;
. .
.

(, yxoedema) ,
.

,
, , , . -
, , , ; -
-. , . -
; ;
; ; .

.
, , , , -
, .

133
 -
, , -
,
.

- -
, , .

-
, .

- -
, , ,
.

, -
, .

, ,
.
,
, . -

,
.

: 3 4 ,
.

:
. -
; -
. -
.

: -
L- (L-Thyroxin) . 50, 100 mcg;
(Euthyrox) . 25, 50, 75, 100 mcg .
, . -

134
 -
.

( )

(Thyroiditis Hashimoto)

: -
.

20 - .

: .
HLA 8/DR5 . -
( ),
( ), -
.

: -
.

: , , -
, .
(),
. -
.
.

: ,
.
-
.

: -
.
.

135
 -
.

(glandula suprarenals) , -
. , -
4-5 g. (-
, cortex), (medulla).
.

3 :

1. () -
- () .

2. () -
, , .

3. , -
-
() ( ).

-
() , .

; ; -

136
 , , -
, .

1.
, .

2. , -
, -
. .

3. -
,
, , .

4.
,
, -
.

(Hypercorticismus) -
,
.

(Hyperglucocorticismus)

( ) (Syndrom Cushing)

: ,
. -
- .

137
 :

1. -
. .
-
. ,
.

2. - -
.
.

3.
(, .).

4. , -
. - ,
.

: -
. .
, -
, , - . -

() . -
-
.

:
, , . -
:

1. -
, , , . -
. 7, -
, ( ), , .
,
, , -
.

138
 2. , -
, , ,
. , , . -
. , , , -
; 2
cm, 20 cm. - .

, ,
. (-
) . -
, ,
.

3.
. -
.

4. -
. -
, -
.
.

5. , ,
, . -
.

6. 50-70% .
.

7. , .

8.
.
( , ). -
,
.

: -
, -
( , -

139
); , -
17- (17--).

: ,
. -
( ),
( ), , -
. -
.

: ,
.

1. , (Mitotan,
Lisodren, Chloditan) 2-12 g/.; 0,5-2 g;
(Metopyron) 1 g/., () 400-1000 mg;

2. , (-
, ) 12-24 mg/.; (Parlodel) 7,5-20 mg/.,
(Dostinex).

-
,
.

( )

(Morbus Addisoni)

:
, -
.

140
 :

1.
70-80% . -
.

2.
.

3. , , -
.

: 90%
.

, .

: , , -
, , , -
.

: , -
. , -
, , , ,
,
.

-
:

1. . -
, .
. ,
, .
, ,
.

2.
, , . -
. -
, N+ -,
-

141
. -
. . -
, - .

3. ( ) ,
98% .
, , , -
, , , , , ,
. -
. -
() (
, ).

4. - , -
, , , -
. -
.

5. , -
. -
.

6. ,
, , .
, , .

: - . -
, , ,
, , .
-
. -
, , ,
, . ,
, . ,
, , , .
, , -
, ,
. , , -
, , , -
.

142
 : -
(17-- 17-) ,
, . -
, , .

, , .

: -
(Prednison), (Prednisolon) 10 mg/. (7,5 mg (2/3 )
+ 2,5 mg (1/3) ).

(Cortineff), -
(Florinef), (Astonin H) 0,05 0,20 mg (1/2 2 .) -
. (-
-) . 50 mg i.m. 3 4 .

, ,
, , . 5-
6 .

-
-

(Sopolcort) 100-200 mg (Urbason) 20-40 mg, -
5% 500 ml + 100 mg 20 mg
. ,
3-4 l/24 h 5%
, .
2-5 mg i.m.
,
, , .

. - -

.
.

143


()
, , -
-
.
. -
, -
.

,
, () -
(). , -

. -
, , , .. -

- .
, -
, , .

1. -
(, , )
.

2. .

3. -
.

4. .

, -
, ,
- .

. -
, .

144
 1 g/kg -
. -
. -
. -
, , -
. 1 g -
4,1 kcal (16,7 J) .
-
, , , .
.

, , , .

.
. .
(, , .), (-
, , ) (, , , -
.). 1 g 4,1 kcal
(16,7 J) .
350-550 g.
. -
( )
3,8-5,5 mmol/l. -
, .

, ,
. -
.
.
,
.
,
.
.
, ,
. -
.

145
 .. (, , -
, , .)
, .. .

().
, .
25-35% , -
, .
1 g 9,3 kcal (37,7 J) . -
,
. -
-
, .
, .
, -
, , .
-
-
, - .

-
,
, , -
( , , ,
).
, , , .

(. ,
, .),
, .

1.
(, , ), (,

146
 LDL, , HDL, -
, ) ( , -
) .

2.
; .

3. () -

. ( 7 h, 12 h, 18 h), (7
h, 12 h, 15 h, 18 h), (7 h, 12 h, 15 h, 18 h, 21 h) ..

4. () 75 g
, 200 ml 5 min. -
0 min ( ,
), 60 min, 120 min 180 min. ,
.

5. -
, -, .

. -
(, BMI), (), -
/, , -
- .

(Diabetes mellitus)

: () , -
, -
, .
-
.

: 1 ( 1, -
) , -
-
2 ( 2, ),
-
, , , .

147
 : -
. -
, , -
. , -
, - 60-70--
. , -
. 250 000 .
,
, ,
.

: , -
. -
:

1.
4-10 -, .
HLA (
) . DR3, DR4,
1 (
95% 1). 2 -
HLA . ,
, .

,
. :

2. -
, , , -
, - .

3.
( ) -
.

4.
, ,
.

5. 2.
80% 2 . ,

148
 2, -
, .
,
,
, -, -
.

1 ( ).
.
.
, 1,
-
( 80%) -
.
,
( , -
, , -
),
(-
, ). -
, .

2 ( ). -
:

1.
;

2. .

2 -
, / -
. , -

( ); - -
-
. ,

149
 --
-
.

.
1. 1
2. 2 ;
3. ()
4. :
( )
(, )
( -
, .)

.
.
V.

1 2

1 2
-




-
40- 40-

0,2% 3%

-
, . :

150
 ( -
, ,
).

: 1 -
, - -
. -
.
. -
, .
( ) -
, .
().
-
, , . -
,
, .
,
.
, (-
). , , ,
. , ( ),
, , , .
, (1),
, , .

1 - , -
. , 1-2
, , (-
)
, ,
, , -
( ) .

2 1,
. -
-
. -
, .

151
 , , ,
, - , 2.
2 -
,
(, ), (, , -
) . -
.
-
.

, -
, .
, .

: -
:

, 1 :
1. > 11,1 mmol/l -
, , , ;
2. > 7,8 mmol/l ,
3. < 7,8 mmol/l +
. , 7,8 mmol/l.
-
.
, , , , -
, .

() ,
, - - -
, - . .

1. < 7,8 mmol/l
2. 120 min 7,8 - 11,1 mmol/l
:

-
. -

152

.
: 10-15%
; 30% , 50-60%
.
10%, -
.
, , , . -
, -
, , , , , ,
, .. -
. -
4-5-, , -
. -
-
, , , -
, , ..

.
2. :

1. ()
.

: (Maninil), (Diaprel MR), -

(Amaryl), (Neoglim), (Gliper), (Limeral) .

1 2
.

: 1, , , -
, .

2. -
-
.

: (Metformin), (Glucophage),
(Siofor), (Metfogamma) . 2-3
.

153
 3. ,
,

.

: (Acarbose), (Glucobay).
3 .

4. -
, .

: (Repaglinide), (Januvia),
(Galvus), (Eucreas), (Trajenta).

, -
2. (Victoza).

, -

, - , -
,
.

, ,

, 2 ,
, .

2.

154
 -

1. 1-2
.

2. , -
. -
( ),
, (-
), -
. -
1:1.

(
- ; -; ), -
(, , -,
) .
.. ( ,
), - -
, - -
-
.

. -
10 ml, 400 , 1
ml 40 . ,
10 ml 1000 , 1 ml 100
. .. -
,
3 ml, 300 -
(1 ml = 100 ).

. , .
30 min 5-8
h. h .

155
 : (Insulin Actrapid),
(InsulinHumulin R), (Insulin Insuman Rapid) .

24 h.
.
.

: (Insulin Novo Lente), -

(Insulin Insulatard), (Insulin Humulin),
(Insulin Insuman Basal) .

-
: 10:90; 20:80;
30:70; 40:60; 50:50. , .

: 30 (Insulin Mixtard 30),

(Insulin Humulin ) .

, - -
.

:
(Insulin Novo Rapid), (Insulin Humalog); -
(Insulin Lantus),
(Insulin Levemir); 30
(Insulin Novo Mix 30), 25 (Insulin Huma Mix 25) .

. ()

- .

.

- : -
, , -
(, , ), -
, , , ,
.

156
 -
. ,
. .
-
(),
.

: ;
; / ; ;
; , (-
), (
), .

: , , , ,
, , , , -
( ), -
, , , .

:
20 mmol/l, 7,3;
18 mmol/l, (-3, -5);
. -
.

: :

1. ( -
6-8 l ). -
, -
. 0,9% ,
5% .
-
.

2. -
6-8-10 /h .
h .

3.
, -

157
, .
. 15% 10 ml.

4. 7,1,
, , 8,4% .

5. , -
.

- 2.
:
1. 35 mmol/l;
2. ;
3. 340 mosm/l;
4. .
, , -
, .

: (, .),
, .

1. 0,9% ;
2. 8-12 /h 0,1
/kg/h;
3.
.

-
, (50%). -
6-7 mmol/l,
/ 30-60:1 ( 10:1).

: -
, -
, ,
. ,

158
 , , , -
.

: , -
,
, .

V.

, -
. -
, .
-
2,8 mmol/l. -
. -
-
2,8 mmol/l ,

.
5-5,5 mmol/l ( -
) -
.

- : -
,
, , -
() .

:
: 1. - -
, (
) 2.
().

(
3,3 mmol/l), -
-
, , . , -
. -

159
 , -
.. .

1. , --
, , , ,
.
, , -
. 5-10 min,
.

2. , , -
, , , , -
, , , ,
, .

2,8 mmol/l.

( )

,





,
3mmol/l


i.v.

160
 : , per os

(1 .. , - .), .
20-
40% ,
10-20% .

1 mg ( ) .

,
() , -
, , -
, .

1.

80% 15 . -
.
.

. -
- , (
) . -
() ,
.. .
, - -
. , ,
, -
.

161
 :
. -
- .

2.

30% 1 20-25% 2 -
.

, , -
,
. -
, .

.. 30-
300 mg /24 h .
-
. 0,5 g/24 h ,
.
,
, , ,
.

:

. 0,6-
0,8 g/g. ., 5 g/
.

3.

1 5-
, 2
12% .

,
, . ,
, .

. , -
, . -

162
 ,
-
. -
.

-
,
.

( ). -
, ( -
), , .

, -
, , -
, ( ).

: , -
. (Milgamma), -
(Thiogamma) ., (Thioctacid) . 600 mg;
(Diamel), . 12; (Erythran),
(Cerucal); (Domperidon).

, (
).

, -
, , .

, ( -
) , -
, , .

-
, , , -
( ). -
,

163
 -
( ).
-

(claudicatio intermitens). -
, ,
. .

: ,
(Trental), (Agapurin), 325 mg;
-
(Dalacin) ., .

(Obesitas)

: e
, ,
- .

,
, 20-30% 30-40% . -
- ,
, - -
.

1. -
.
( , )
,
, .

2. -
. 10 ,
.
, -
, .

164
 3. -
, -
.

4.
.
, , . -
(, , .) -
- -
, .

5. (
.), ( -
), .

1. -
(). ,
. .

2. . -
- , -
- .
, -
.

:
. ,
, , .
-
(, body mass index BMI),
:
BMI
20
20-25
25-30
30-40
40

165

-. -
(: /):

(, )
, ,
, , .
(/ >1,0), (/ > 0,8)
. -
- -
, ., . -
.

- ()
, .
(/ < 0,8), (/ < 1,0) -
.

, -
, -
. -
.
-
, .

1.

2. - - -
. , 10%
6,6 mmHg,
0,11 mmol/l, 0,12 mmol/l.

3. -

,
.

4. -
, .

166
 5. - ,
, .

6. , -
, .

: -
, ,
- -
.

1. , -
, 30% -
300 mg/, -
(, , ) -
,
. ,
500 kcal - .

2.
,
, .

3. -
. -
-
.

4. :

-
-
. -
, ,
. , (),
(), ().

(Xenical, Orlistat)

.

167
 ,
. - -
- .

(Podagra)

: ,
.

- .

-
. , - -
.
. 380 mcmol/l,
, 540
mcmol/l, 90%. -
, -
, .

: , -
, -
.
.
-.
, , , -
, .

, -
, .

: :

1.
, .

2. - -
. , -
, . -

168
 , . - -
( ),
, , ,
.
, - -
. 1-2 .
, -
- - .

3.
,
.

4. -
()
, (), (), , ,
.
.
.

: - -
; -
, , .

169
 . , -
. -
, -
.

: , (
), , .

: .
, (-
, , , , , , ). -
(
). -.
, .

, 1,5-2,5 l ., ;
(Soluran).

(Colchicin) . 0,5 1 mg. -
1-2 .


() (Indometacin); (Feloran);
(Ibuprofen); (Profenid); (Pyroxicam); (Aulin);
(Diclofenac); (Voltaren); (Naproxen); -
(Movalis); (Tilcotil); (Nurofen) .
, , -
(Allopurinol, Milurit) .
100, 300 mg., (Febuxostat, Adenuric) 80-120 mg/., -
(Desuric).

1.
(, ) ;

170
 2. ( -
, , , -
..) -
;

3. ;

4. , -
, , cm;

5.
, ;

6.
9 8
;

7.
;

8. , -
;

9. , -
(, , , ), ,
, -
;

10. -
, , , , ..;

11. , -
, , -
, -
;

12. -
, -
-
;

171
 13. -
( 24- , 17--
, , .):

,
;

: -
, ( , ), , ,
, , , , , -
;

( , , )
;

()
, , , ;

-
;

-
;

14.
:

, -
, ;
,
;
-
;
.

172
 15. -
- :
-
;
-
;
;
75 g
;
-
, , , ;
.
16. :
;

( )
;

, ,
1 ml 2 ml 40 UI , 1/10 ml 4 UI;

,
, .

17. -
:

,
. -
, ;

173

1 ,
;

-
( 6 mm) 900. , -
0 . 5 s .

-
.

18. , -

, -
,
, , ..

19. -
;

20. -
, ,
;

21.
:

, (, , -
.), - , ,
..;

174
 -
.

22.
:

-
;

-
, ;

-
,
.

23.
- ( ) -
:

-
;

, -
;

-
, ;

23. -
(, ,
, .):

-
;

175
 ;

-
;

-
;

, -

, , , ;

,
;

-
;

1. , . . ., . ., 1992, 589 .
2. , . .
., -2001, 2009, 143.
3. . . . - . . , , 1994.
4. , . . , , 2006, 460 .
5. , . (- ). -
, -, 2007, 375 .
6. , ., . . . ., IP Bulgaria, 2007,
349-368.
7. , . . ., . ., 2002, 813 .
8. , . (.). . ., , 2000, 1100 .
9. . . . . ..,
, . , 2008, 432.
10. , . . . ,
, 2009, 296 .
11. , . . . ., 2002.
12. , . . . ., , 2005, 106 .
13. . . . . . . . .,
. ., 1987.

176
14. , . . .,
, 2012, 208 .
15. , . . ., 2002.
16. A d l e r , A. I. et al. Association of systolic blood pressure with macrovascular and microvascular
complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ, 321,
2000, 7258, 412-419.
17. A l l a h a b a d i a , A.et al. Diagnosis and treatment of primary hypothyroidism. BMJ, 338,
2009, b725.
18. A m e r i c a n Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice
for the Diagnosis and Treatment of Acromegaly. Endocrine Practice, 10, 2004, 3, 213-225.
19. A m e r i c a n Association of Clinical Endocrinologists. Medical Guidelines For Clinical Practice
For The Evaluation And Treatment Of Hyperthyroidism And Hypothyroidism. Endocrine
Practice, 8, 2002,6, 457-469.
20. A m e r i c a n Diabetes, Association. Diagnosis and classification of diabetes mellitus.
Diabetes Care, 35, 2012, Suppl. 1, S64-71.
21. A m e r i c a n Diabetes Association. Hyperglycemic Crises in Patients With Diabetes. Diabetes
Care, 27, 2004, (S1), 94-101.
22. A m e r i c a n Thyroid Association (ATA). Hypothyroidism Booklet, 2003, 4-6.
23. A y u k , J, Sheppard MC. Growth hormone and its disorders. Postgr. Med. J., 82, 2006, 24-30.
24. B r o n s t e i n , M. D. Potential for long-term remission of microprolactinoma after withdrawal of
dopamine-agonist therapy. Nat. Clin. Pract. Endocrinol. Metab., 2, 2006, 3, 130-131.
25. B u r n s , C. et R.Wortmann. Gout therapeutics: new drugs for an old disease. Lancet, 377,
2011, 165-177.
26. C a r s o n , P. P. Emergency.Adrenal crisis. Am. J. Nurs., 100, 2000, 7, 49-50.
27. C h i a s s o n , J-L., N. Aris-Jilwan et R. Belanger. Diagnosis and treatment of diabetic
ketoacidosis and the hyperglycemic hyperosmolar state. CMAJ, 168, 2003, 7, 859-866.
28. C o l a o , A. et al. Medical treatment of prolactinomas. Nat. Rev. Endocrinol., 7, 2011, 267.
29. C r y e r , P., S. Davis et H. Shamoon. Hypoglycemia in Diabetes. Diabetes Care, 26, 2003,
1902-1912.
30. C r y e r , P. E. et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine
Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab., 94, 2009, 3, 709-728.
31. C z e p i e l e w s k i , M. A. et al. Criterai of cure and remission in cushings disease: an update.
Arg. Bras. Endocrinol. Metabol., 51, 2007, 8, 1362-1372.
32. E l e d r i s i , M. S. et al. Overview of the diagnosis and management of diabetic ketoacidosis.
Am. J. Med. Sci., 331, 2006, 5, 243-251.
33. E n g l i s h , P. et G.Williams. Hyperglycemic crises and lactic acidosis in diabetes mellitus.
Postgrad. Med. J., 80, 2004, 253-261.
34. F a s a n m a d e , O. A., I. A. Odeniyi et A.O. Ogbera. Diabetic ketoacidosis: diagnosis and
management. AJMMSci, 37, 2008, 2, 99-105.
35. F r a n k l y n , J. A. The management of hyperthyroidism. N. Engl. J. Med., 330, 1994, 24,
1731-1738.
36. H a d j i z a c h a r i a , P. et al. Acute diabetes insipidus in severe head injury: a prospective study.
J. Am. Coll. Surg., 207, 2008, 4, 477-484.
37. H e r d e r , C. et M. Roden. Genetics of type 2 diabetes: pathophysiologic and clinical relevance.
Eur. J. Clin. Invest., 41, 2011, 6, 679-692.
38. H o l d a w a y , I. M. Treatment of acromegaly. Hormone Research., 62, 2004, Suppl. 3, 79-92.
39. H o t z e , L. A. et P. M. Schumm-Draeger Schilddrsenkrankheiten. Diagnose und Therapie.
Berlin, 2003.

177
40. H u r l e y , D. M. et K. K. Y. Ho. Pituitary disease in adults. Med. J. Australia, 180, 2004, 419-
425.
41. J o f f e , R. T., M. Brimacombe, A. J. Levitt, A. Stagnaro-Green. Treatment of Clinical
Hypothyroidism With Thyroxine and Triiodothyronine. A Literature Review and Metaanalysis
Psychosomatics, 48, 2007, 5, 379-384.
42. K i t a b c h i , A. E. et al. Hyperglycemic crises in adult patients with diabetes: a consensus
statement from the American Diabetes Association. Diabetes Care, 29, 2006, 12, 2739-
2748.
43. L e v y , A. Pituitary disease: presentation, diagnosis, and management. J. Neurol. Neurosurg
Psych., 75, 2004, 47-52.
44. M a l i k , V. S. et al. Sugar-Sweetened Beverages and Risk of Metabolic Syndrome and Type 2
Diabetes: A meta-analysis. Diabetes Care, 33, 2010, 11, 2477-2483.
45. M a n n , W. A. Treatment for prolactinomas and hyperprolactinaemia: A lifetime approach.
Eur. J. Clin. Investig., 41, 2011, 334.
46. M e l m e d , S. et D. Kleinberg. Pituitary masses and tumors. In: Kronenberg HM, Melmed S,
Polonsky KS, Larsen PR, eds. Williams Textbook of Endocrinology. 12th ed. Philadelphia, PA:
Saunders Elsevier; 2011:chap 9.
47. M e l m e d , S. et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society
clinical practice guideline. J. Clin. Endocrin. Metabol., 96, 2011, 273.
48. M o r r i s , D. et A. Grossman. The medical management of cushings syndrome. Ann. N. Y.
Acad. Sci., 970, 2002, 119-133.
49. N a t h a n , D. M. et al. Intensive diabetes treatment and cardiovascular disease in patients with
type 1 diabetes. NEJM, 353, 2005, 25, 2643-2653.
50. N e o g i , T. Gout. N. Engl. J. Med., 364, 2011, 443-452.
51. O c h s , N. et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart
disease and mortality. Ann. Intern. Med., 148, 2008, 11, 832-845.
52. Q a s e e m , A. et al. Clinical Guidelines Committee of the American College of Physicians. Oral
pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the
American College of Physicians. Ann. Int. Med., 156, 2012, 3, 218-231.
53. R i p s i n , C. M., H. Kang, et R. J. Urban. Management of blood glucose in type 2 diabetes
mellitus. Am. Fam. Physician, 79, 2009, 1, 29-36.
54. R i s r u s , U., W..C. Willett et F.B. Hu. Dietary fats and prevention of type 2 diabetes.
Progress in Lipid Research, 48, 2009, 1, 44-51.
55. R o b e r t s , C. G. et P. W. Ladenson. Hypothyroidism. Lancet, 363, 2004, 9411, 793-803.
56. S a m u e l s , M. H. Cognitive function in untreated hypothyroidism and hyperthyroidism. Curr.
Opin. Endocr., Diabetes and Obesity, 15, 2008, 5, 429-433.
57. S e c k l , J. et D. Dunger. Postoperative diabetes insipidus. BMJ, 298, 1989, 6665, 2-3.
58. S m y t h , S. et A. Heron. Diabetes and obesity: the twin epidemics. Nature Medicine, 12,
2006, 1, 75-80.
59. T e n , S., M. New et N. Maclaren. Addison`s Disease. J. Clin. Endocrinol. Metab., 86, 2001,
2909-2922.
60. V a n d e Walle, J. et al. Desmopressin 30 years in clinical use: a safety review. Curr. Drug
Saf., 2, 2007, 3, 232-238.
61. V i j a n , S. Type 2 diabetes. Ann. Int. Med., 152, 2010, 5, ITC31-15.
62. W i l d , S. et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for
2030. Diabetes Care, 27, 2004, 5, 1047-1053.
63. W o r l d Health Organization. Definition, diagnosis and classification of diabetes mellitus and
its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of
diabetes mellitus. Retrieved 29 May 2007.

178


()

-
,
.

1. , -
, ;

2. , , -
.

()

(Lupus erythematodes disseminatus)

: -
, -
.

- 10:1
30:1. .

: . -
, . -
, , -
, , .

: -
, - ,
, , .
,
, , ,
, .

: ,
. - ,

179
 . -
-.

. ,
, ( ).
, ,
. .

, , -
. , , , .
- , -
.
, . -
. -
, , .
.

, -
, .

-
, .
, , .
.

. -
, , ,

180
, , ,
S- - .

-
. .. ,
. -
. -
, , .

- , , ,
, ,
, . (
).

() , -
,
, , .
.

- , .

,
-, C- ,
, , .

: - -
(
), L (
), -
, , .

: 4 11 :

1.
, ;

181
 2.
;

3. ;

4. ;

5. , , ;

6. , ,
, ;
, , ;

7. 0,5 g/.,
+++, , ;

8. , ;

9. , ,
, ;

10. L ,
- -
( ) 6 .

11.

1. , -
, ;

2. () -
(Aspirin), (Ibuprofen), (Diclofenac),
(Feloran) .;

3. -
.
(Prednisolon), (Dehydro-
cortison), (Urbason), ;

4. (Arthrochin),
(Resochin), (Plakenyl);

182
 5. (Ciclophosphamid),
(Azathioprin);

6. , , , -
.

()

(Sclerodermia progressiva disseminata)

: , -

. , -
. -
, .

, -
- , 30 50 .

:
-
, ( , -
, - , - .), -
.

:
:

-
,
,
- .

, (-
) -
. - , -
. -
, ,
.

183
 -
. - , -
, , .
(-). -
(),
(), -
.
()
, ().

-
.

, -
. ,
.

- , -
, , .

,
. -

;
, , .

: -
, ,
-.
.

,
, , .

184
 -
, , -
(, ), () .

D--
, , .

, , (-
, ).

( Rituximab), , -
.

(Polymyositis et dermatomyositis)

: () () -

, ,
, .

:

, ., .

, , . -
, .

: -
(), , -
. -
.

: - -
. -
, -
. - -
, , , ,

185
. ,
, , , -
, . -
.
, -
, .

-
- . ,
(), , ..

:
. -
(--); ();
.

: , -
, (), .

: , , -
.

(Panartheriitis nodosa)

. -
-

, -
.
.

-
,
.

: .

186
 : -

.

: , , -
- , ,
.
, -
, , . -
, , , . -
,
, -
. ,
. , -
, , . -

.

: ,

1. . . . - . . , , 1994.
2. , . . ., . ., 2002, 813 .
3. . . . . . . . .,
. ., 1987.
4. , . . ., 2002.
5. A l l e n , N. B. et P. B. Bressler.Diagnosis and treatment of the systemic and cutaneous
necrotizing vasculitis syndromes. Med. Clin. North Am., 81, 1997, 1, 243-259.
6. B a l o w , J. E. Clinical presentation and monitoring of lupus nephritis. Lupus, 1, 2005, 14,
25-30.
7. B o u m p a s , D. T., Pr. Sidiropoulos etG. Bertsias. Optimum therapeutic approaches for lupus
nephritis: what therapy and for whom? Nature Reviews Rheumatology, 1, 2005, 22-30.
8. B u r t , R. K. et al. Intense Immune Suppression for Systemic Lupus The Role of
Hematopoietic Stem Cells. J. Clin. Immunol., 20, 2000, 1, 31-37.
9. C a l l e n , J. P., etR. L. Wortmann. Dermatomyositis. Clin. Dermatol., 24, 2006, 5, 363-373.
10. C a l l e n , J. P. Immunomodulatory treatment for dermatomyositis. Current Allergy and
Asthma Reports, 8, 2008, 4, 348-353.
11. C a r l s o n , J. A., B. T. Ng, K. R. Chen. Cutaneous vasculitis update: diagnostic criteria,
classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am. J.
Dermatopathol., 27, 2005, 6, 504-528.

187
12. C a r l s o n e , J. A., L. F. Cavaliere et J. M. Grant-Kels. Cutaneous vasculitis: diagnosis and
management. Clin. Dermatol., 24, 2006, 5, 414-429.
13. D o r i a , A. et M. Petri. Cardiac Involvement in Systemic Lupus Erythematosus. Handbook of
Systemic Autoimmune Diseases, 1, 2003, 145-161.
14. F a t h i m , M, I. E. Lundberg et G. Tornling. Pulmonary Complications of Polymyositis and
Dermatomyositis. Semin. Respir. Crit. Care Med., 28, 2007, 4, 451-458.
15. G h a t e , J. et al. A therapeutic update on dermatomyositis/polymyositis. Int. J. Dermatol., 39,
2000, 2, 81-87.
16. G u i l l e v i n , L, F. Lhote et R. Gherardi. Polyarteritis nodosa, microscopic poly angiitis,and
churg-straus syndrome:clinical aspects,neurologic manifestations and treatment. Neurologic Clinics,
15, 1997, 4, 865-886
17. H a r a , M. et al. Prospective study of high-dose intravenous immunoglobulin for the treatment of
steroid-resistant polymyositis and dermatomyositis. Modern Rheumatology, 13, 2003, 4, 319-
325.
18. H a u p t , H. M. ,G. W. Moore et G. M. Hutchins. The lung in systemic lupus erythematosus:
Analysis of the pathologic changes in 120 patients. AJM, 71, 1981, 5, 791-798.
19. H i l t o n - J o n e s , D. Inflammatory muscle diseases. Current Opinion in Neurology, 14, 2001,
5, 591-596.
20. H i r a k a t a , M., S. Nagai.Interstitial lung disease in polymyositis and dermatomyositis.
Current Opinion in Rheumatology, 12, 2000, 6, 501-508.
21. H u b e r , A. M. Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment.
Pediatric Drugs, 11, 2009, 6, 361-374.
22. H u g h e s , L. B. et S. L. Bridges. Polyarteritis nodosa and microscopic polyangiitis: etiologic
and diagnostic considerations. Current rheumatology reports, 4, 2002, 1, 75-82.
23. K o v a c s , S. O. et S. C. Kovacs. Dermatomyositis. J. Am. Acad. Dermatol., 39, 1998, 6,
899-922.
24. L h o t e F., P. Cohen L. Guillevin. Polyarteritis nodosa, microscopic polyangiitis and
ChurgStrauss syndrome. Lupus, 7, 1998, 4, 238-258.
25. M a n d e l l , B. F. Cardiovascular involvement in systemic lupuserythematosus. Seminars in
Arthritis and Rheumatism, 17, 1987, 2, 126-141.
26. M a r z a n o , A.V., E. Berti et C. Gasparini. Lupus erythematosus with antiphospholipid
syndrome and erythema multiforme-like lesions. Br. J. Dermatol., 141, 1999, 4, 720-724.
27. M a t t h a y , R. A., S. I. Bromberg et C. E. Putman. Pulmonary renal syndromes a
review. Yale J. Biol. Med., 53, 1980, 6, 497-523.
28. M i l l e r , F. W. Inflammatory myopathies: polymyositis, dermatomyositis, and related
conditions. Clinical Primer of Rheumatology, 2003.
29. R a m o s - C a s a l s , M. et al. Targeted therapy for systemic sclerosis: how close are we? Nat.
Rev. Rheumatol., 6, 2010, 5, 269-278.
30. S a l e h , A. et J. H. Stone. Classification and diagnostic criteria in systemic vasculitis. Best
Practice and Research Clinical Rheumatology, 19, 2005, 2, 209-221.
31. S t o n e , J. H. et H. C. Nousari. Essential cutaneous vasculitis: what every rheumatologist should
know about vasculitis of the skin. Current Opinion in Rheumatology, 13, 2001, 1, 23-34.
32. S u l t a n , S. M., Y. Ioannou et D. A. Isenberg. A review of gastrointestinal manifestations of
systemic lupus erythematosus. Rheumatology, 38, 1999, 10, 917-932.

188
33. T a k a d a , K, K. Nagasaka et N. Miyasaka. Polymyositis/dermatomyositis and interstitial lung
disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity, 38,
2005, 5, 383-392.
34. T a r g o f f , I. N. Laboratory manifestations of polymyositis/dermatomyositis. Clin. Dermatol.,
6, 1988, 2, 76-92.
35. V a l a n i e n , G., D. Jasaitien eet S. Valiukeviien. Pathogenesis and treatment modalities of
localized scleroderma. Medicina (Kaunas), 46, 2010, 10, 649-656.
36. V a n L a a r , J. B-cell depletion with rituximab: a promising treatment for diffuse cutaneous
systemic sclerosis. Arthritis Research and Therapy, 12, 2010, 2, 112.
37. V i r e n d r a , S. N. et al. Lupus Miliaris Disseminatus Faciei Part II: An Overview. SKIN Med.
Dermatology for the Clinician, 4, 2005, 4, 234-238.

189


- -
,
, .

1. ;
, .
2. ()
3.
4. , , .

-
,
, , ,
. -
.
, ..

-
, ,
, , , ..
,
. -
:

1. , , ;
2. , ,
(); -
() ..

190
 3. -
;
4. -
.
, , .
5. , ;
6. , -
, , .;
7.
, .
.

, , -
, - , -
-; .; , .
LE LE ;
;
.

( ), -
, , , ;
; -
.

1. ()

-
, , ,
.;

(-
) , , -
.

191
 2. () (-
) , , , -
.

3. - , .

4. , -
, , .

(Arthritis rheumatoides)

: , -
,
,
.

, ,
., .

3 - ,
.

: . -

. -
( ), ,
, , .

: -
, .
-
. ,
, 2
, .
-
.

192
 : , ,
, , -
, .
, -
, .

-
, , -

.

: , , -
, , .

, - .
. -
, , . -
. -
-
, , , , -
. - , , -
.
, -
, , . -
.

( V) -
;

W, -
Z;

mm. interossei

, -
.

193
 :

, -
.

.
.

,
( -
). .
, .

,
.

; -
, , - .

-
.

, , .

194
 ;
, ;
, ; -
.

: ,
-2-; (
Waaler-Rose 1:64 1:32); (. -
, );
. ,
, .

: -
. 4 :

.
.
.
V .
: 6 4 + 1
+ 1 :

, 1 ,
3 , 1 (
), , -
.

( 1:32).

4 .

: :

(Acetysal,
Aspirin) t. 0,500; (Ibuprofen, Brufen, Profenid);
(Indomethacin) t. 25 mg, supp. 50 mg; (Diclofenac),
(Feloran) t. 25, 50, 100 mg; supp. 50, 75 mg; amp. 75 mg,
(Voltaren) t. 25, 50, 100 mg; amp. 75 mg; (Phenylbutazone,

195
Butadion) t. 200 mg; (Eumotol) t. 110 mg;
(Piroxicam) t. 10, 20 mg; (Naproxen) 250 mg

:
(Arthrochin) t. 250 mg; (Resochin) t. 250 mg;
Delagil t. 250 mg; (Solganal B oleosum)
amp. 50 mg; (Allocrysine) amp. 50 mg; D-
(Cuprenil t. 150, 200 mg; D-penicillamine- t. 250 mg);
(Salazopyrine) t. 500 mg;
(Imuran) t. 50 mg; -
(Cyclophosphamid) t. 50 mg, amp. 200 mg;
(Metothrexate) t. 2,5 mg, amp. 15 mg
(Prednisolon) t. 5 mg; -
(Methylprednisolon) i.v. - .
-
.. ,
. :
(Etanercept, Enbrel), (Infliximab), (Humira), -
(Rituximab) .

( )

(Spondyloarhthritis ankylosa; Morbus Bechterewi)

: () -
, . -
, -
.
.

,
.

196
 15-25- -
. 3 - .

:
HLA 27 , 90-95% .
, , -
, .
.

: -
, () -
. -
,
, . -
.
() ,
( ).

: -
, , . -

197
 (), , -
, .
, , -
.
( .)
.
.
.

1. - ;

2. - -
(, );

3.
(, , ),
( ); ().

-,
. ,
- - .

:
. -
, -2-, -; 27-.
-
, 4 :

0 . , ;

. ,
;

. ;

. ;

V . .

.. ,
- 12- 1- .

198
 ,
.

: :
1. 3 ,
;
2. -
;
3. 2,5 cm .

:
-
( .); -
;
; , .
, -
, , , , , , .
(Salasopyrin) -
,
( ).
,

(Adalimumab, Etanercept, Infliximab).

(Osteoarthrosis)

: -
,
.
-
.

1. -
, -

199
 . , -
,
, .

2. -
,
, . -

. -
- ,
.

3.
. -
.

4.
.

5. -
. , .
.

6.
( ), ., -
.

7.

, .

8. ,
. -
, , -
.

9. -
.

: , -
, :

200
 -
;

, . ,
, ,
(), -
- .

,
, .

:
, . -
- , -
, ,
.

. -
, , -
, ,
. .
, -
. , .

.
, -
. , -
. . -
, , ,
.
. -
; 10-
15 min.
, , ,
.

, .

201
 :
:

-
;

-
;

, .

( ),
,
, -
, .

: :

( );

, .
;

1. -
;

2. ;

3. ;

4. :

, , .

-
, , , , , -2
(Celecoxib), (Dynastat), (Nimesulide) .

202

, .

(Midocalm) -
, .

-
, -
. ,
, , -
,
, , -
. (Flexodon),
(Hodronic), .

5. , -
.

, .

:
:

1.
;

2. -
;

3. -
.

: -
.
, -
.

203
 -
.
. -
.

:
. - -
. - , , -
. , ,
. ,
. -
, , -
.

: , -
, , .,
. -
.

(Osteoporosis)

: - -
. -
, -
- ,
.

20- , -
20- 35-
, (,
) (,
).
-
, ,
.

: :

204
 1. , -
, .
2. -, ,
. D, , .
3. , -
, , .
4.
, .
5. , , ,
.
6. , ,
, , ,
, .
- , -
, .

1.

( 1) 45- 65-
. .
( 2) 70- . -
-
. D , . D .
2. , , -
, , .

205
 : ,
-
, , .
,
. -
.
, , -
. , ,
. (6-8 .) -
, ,
- -
, , .
,
, .. .
. ,
- .

-
, - .

- , -
6 . -
- .

: -
(). - ( = , -
= )
(DXA).
- .
(QUS), -
(QCT). -
.

: :

1. . D
. -
( )
50 . 1500-2000 mg/.

206
 2.

3. :

(, Fosamax 70 mg 1 .
.; , Lindron 10 mg 1 . .), (, Bonviva
150 mg 1 . .), (, Aclasta) .

200

4. -

(Osseor, Protelos) 1

-
, .

5. -
-
, -
/.

() -
.

: -
.
, , .

( ) , -
, . -
, , ,
, , , -
.

: -
-
, , .

207
 - .
, -
.
, -
. - -
. -
.

-
. , -
.

: - -
. -
, ,
; .

1.
(, );

2. ( -
, , ,
..) ;

3. ;

4.
, ;

5.
, -
;

6. ,
, -
;

208
 7. , -
(, , , ), ,
-
;

8. -
(, , ,
), , , ..;

9. , -
, ,
,
;

10. ( -
, , , .)
, -
-
;

11. ,
, .;

12.
-
;

13. -
;

14. ,
;

15. -
, , .;

16. -
( ,
,
, , -
, .);

209


1. , . -
, . , 11 ,2011, 4,
77.
2. , . . ., . ., 1992, 589 .
3. . . . - . . , , 1994.
4. , . . ., . ., 2002, 813 .
5. , . . Health bg., 2011, 44-47.
6. . . . . . . . .,
. ., 1987.
7. , . . . . -
, 2002.
8. , . . ., ,
2012, 208 .
9. , . . ., 2002.
10. , . . ., . ., 1990.
11. A m e r i c a n College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines.
Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum., 46,
2002; 328-346.
12. A n k y l o s i n g Spondylitis. Humira (adalimumab) drug information website. Abbott
Laboratories. Retrieved, 29 October, 2011.
13. B i j i l s m a , J. Diagnosis and nonsurgical management of osteoarthritis. Ann. Rheum. Dis., 60,
2001, 6, 1136.
14. B i s c h o f f - F e r r a r i , H. A. et al. Prevention of nonvertebral fractures with oral vitamin D and
dose dependency. Arch. Int. Med., 169, 2009, 6, 551-561.
15. B o e r s , M. Rheumatoid arthritis. Treatment of early disease. Rheum. Dis. Clin. North. Am.,
27, 2001, 405-414.
16. D e i g h t o n , Chr., R. OMahony, J. Tosh, Cl. Turner, M. Rudolf et Guideline Development
Group. Management of rheumatoid arthritis: summary of NICE guidance. Br. Med. J., 338,
2009, 710-712.
17. E l y a n , M. et M. A. Khan. Diagnosing ankylosing spondylitis. J. Rheumatol., 78, 2006, 12-23.
18. E m e r y , P. et al. Early referral recommendation for newly diagnosed rheumatoid arthritis:
evidence based development of a clinical guide. Ann. Rheum. Dis., 61, 2002, 290-297.
19. F e l d t k e l l e r , E. et al.Age at disease onset and diagnosis delay in HLA-B27 negative vs.
Positive patients with ankylosing spondylitis. Rheumatology international, 23, 2003, 2, 61-
66.
20. F e l d s t e i n , A. et al. Bone mineral density measurement and treatment for osteoporosis in older
individuals with fractures. Arch. Int. Med., 163, 2003, 18, 2165-2172.
21. G o l d r i n g , S. R. A 55-year-old woman with rheumatoid arthritis. JAMA, 283, 2000, 524-
531.
22. G r e e n s p a n , S. L. et al. Combination therapy with hormone replacement and alendronate for
prevention of bone loss in elderly women. JAMA, 289, 2003, 19, 2525-2533.
23. H e a l y , P. J. et P. S. Helliwell. Classification of the spondyloarthropathies. Curr. Opin.
Rheumatol., 17, 2005, 4, 395-399.
24. H u i z i n g a , T. W et T. Pincus. In the clinic. Rheumatoid arthritis. Ann. Intern. Med., 153,
2010, 1.
25. J i m n e z - B a l d e r a s , F. J. et G. Mintz. Ankylosing spondylitis: clinical course in women and
men. J. Rheumatol., 20, 1993, 12, 2069-2072.

210
26. K h a n , M. A. HLA-B27 and its pathogenic role. J. Clin. Rheumatol., 14, 2008, 1,50-52.
27. K i m , T. H., W. S. Uhm et R. D. Inman. Pathogenesis of ankylosing spondylitis and reactive
arthritis. Curr. Opin. Rheumatol., 17, 2005, 4, 400-405.
28. M a j i t h i a , V. et S. A. Geraci. Rheumatoid arthritis: diagnosis and management. Am. J. Med.,
120, 2007, 11, 936-939.
29. M a k s y m o w y c h , W. P., D. Elewaut et G. Schett. Motion for debate: The development of
ankylosis in ankylosing spondylitis is largely dependent on inflammation. Arthritis and
Rheumatism, 64, 2012, 6, 1713-1719.
30. M c L e o d , C. et al. Adalimumab, etanercept and infliximab for treatment of ankylosing
spondylitis: a systematic review and economic evaluation. Health Technol. Assess, 11, 2007,
28, 1-158.
31. O ' D e l l , J. et J. R. O'Dell. Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med.,
350, 2004, 25, 2591-2602.
32. P a v e l k a , K. et al. Glucosamine sulphate use and delay of progression of knee osteoarthritis: a
3-year, randomised, placebo-controlled, double-blind study. Arch. Intern. Med., 162, 2002,
18, 2113-2123.
33. R e c o m m e n d a t i o n s for the prevention and treatment of glucocorticoid-induced
osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on
Glucocorticoid-Induced Osteoporosis. Arthritis Rheum., 44, 2001, 1496.
34. R e g i n s t e r , J. et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a
randomised, placebo-controlled clinical trial. Lancet, 357, 2001, 251-256.
35. R i n d f l e i s c h , J. A. et D. Muller. Diagnosis and Management of Rheumatoid Arthritis. Am.
Fam. Physician., 72, 2005, 6, 1037-1047.
36. R o d r i g u e z - E s c a l e r a , C. et A. Fernandez-Nebro. The use of rituximab to treat a patient
with ankylosing spondylitis and hepatitis B. Rheumatology, 47, 2008, 11, 1732-1733.
37. R o n a , Z. Osteoarthritis. Natural Health Guide, 2002.
38. R o s e n , H. N. Bisphosphonates in the management of osteoporosis in postmenopausal women.
http://www.uptodate.com/home/index.html. Accessed Oct. 26, 2011.
39. R o s e n , C. J. Parathyroid hormone therapy for osteoporosis. http://www.uptodate.com/home/
index.html. Accessed Oct. 26, 2011.
40. S c o t t , D. L., F. Wolfe et T. W. Huizinga. Rheumatoid arthritis. Lancet, 376, 2010, 9746,
1094-1108.
41. T i w a n a , H. et al.Correlation between the immune responses to collagens type I, III, IV and V
and Klebsiella pneumoniae in patients with Crohn's disease and ankylosing spondylitis.
Rheumatology, (Oxford), 40, 2001, 1, 15-23.
42. T o i v a n e n , A. et T. Mttnen. Ankylosing spondylitis: current approaches to treatment.
BioDrugs, 10, 1998, 3, 193-200
43. V a n E v e r d i n g e n , A. A. et al. Bijlsma. Low-dose prednisone therapy for patients with early
active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects.
Ann. Intern. Med., 136, 2002, 1-12.
44. W a s s e r m a n , A. M. Diagnosis and Management of Rheumatoid Arthritis. Am. Fam. Phys.,
84, 2011, 11, 1245-1252.
45. Z h a n g , X. et al. Prospective cohort study of soy food consumption and risk of bone fracture
among postmenopausal women. Arch. Int. Med., 165, 2005, 16, 1890-1895.

211


(Intoxicationes acuta)

: ,
, -
,
/ .

-
, , , .
:
1. .
-
.
2. -
, .
3. , -
.
4. -
, - .
:

, , -
, .;

, .
, :

, -
, (, .),
, .;

, ;

212
 .


.
, :

.
, , :

, , -
, .

, - -
, , ;

, , ,
, , ;

,
, , ;

, , ( );

- -
, .
,
.
, -
, .

213


-
.

,
.
, -
.

1. ,
, ,
.
( , ) -1 amp. 1 ml
1% .

2. -
, .
3-4 (1-3 ..)
, .,
. -
- , -
, , , ,
, .

3. ,
, , -
.

4. 30 g -
.

5. 2 .

6.

7. -
:

, (
);

214
 () , 1-3%
, , CaNa2 EDTA -
.

8. -
, -
: -
2, ; - -
( +
+ );
, , , , .;
,
, .; , -
, ..

() . -
, -
. , -
.

: , -
, , -
..
. ,
- . .
.
. ,
, , . -
- .

: .

1. ;

2. Antidotum
metallorum;

215
 3. ,
(D-);

4. , , -
, .

(Intoxicatio cum carboneo oxydato)

: ,
;
; ,
, .

: .
, , -
2
. ,
(, .)
,
.

: -
,
.
.

: , -
, , , , .
.

2 4 , , -
,
. ,
, , .

, -
(, .). -

216
 ;
, ;
-
. ,
(). .

, -
.

, ,

, , , ,
, -

- , , - ,
, , -
,
- , -
, , -

: .

1. .

2. 2
;
, 2, -
.

3. , 3-4 1 ./.

4. -
2 80 mg, 10% 250 ml, i.m, i.v.

5. -
; . .

6. .

217
 7. -
.

8. , .

0,10 g
0,20 g ; 2 g.

: 15 min -
, ,
, , ,
. ;
. ,
(). -
, 34-330 -. -
.

: .

( ) -
( 1/1000 = 1
), ,
;
-1 mg 1-2
. 1% 1 ml, (Naloxon) . 400 mg (-
);
- , , , -
;
2 ;
;
;
.
40%.

218


- ,
. 1 g, 0,10
g/kg .

: -1
,
. , , -
, . -
. ,
38-390 , .

: .

( )
;
30 g ;
, ;
, , -
, ;
2 ;
, ;
;
.
.

-
.
, -
-
.

219
 , -
1-1,5 g//. ( 100-150 g), 4 g//.

: , -
, , -
, , , .

-
, , -
,
. , ,
. , -
, , .

.

: .

,
;

( )
;

- , ;

, ;

, ;

- .

, ( ), -
( ) ( -
).

0,003 - 0,004 g ;
0,100 g.

220
 : 10-15 min -
. , , ,
. ,
. . , .
. -
, , , -
, .

: .

( )
;

30 g ;

0,01 g 1-2 h -
;

, , ;

2 ;

, ;

- ;

; -
12 h.

(Mycetismus)
- -
.

(Amanita phalloides).
-
.

221
 : 12-48 h
, , -
, . 2-3
, . -
,
.
: .
;
( )
;
30 g ;
, -

;
, , -
,
. -
, .
( -
Silybum Marianum).
, , , -
.
40-60%. -
.

(Amanita muscaria
).

: 3 h
, , , () -
; - -
, .

222
, , ,
.

: .

( )
;

30 g ;

, , 2;

, , -
.

( )

-
, ,
.

- , -
.

, ,
., -
.

() . -
-
, , .
, .

223
 (),
.

: 20-30 min -
. , , ,
, . -
, , , -
-
. ,
, , -
. -
- .

: .

1. .

2. 100 g -

;

3. ;

4.
1-3 mg 15-20 min s.c./i.v. ;

5. - , -
, , 2 , , .

: ; -
.

( -
5-10 g), , , ( 15-30 g),
( 1-3 g) .

, . -
. -
, ( , , ),
, .

224
 : -
,
, , , .
, , -
, , - .
, -. -

, ,
-
. - (
).

: .

1. .

2. - , -
, .

3. ;

4. , -
;

5. , - -
.

: . -
- . ,
, , ,
.

, -
. 0,20-0,50 g. -
, , -
, .
, -
, , . -
,
, -

225
 ( , , ).
, ()
.

: , -
, 40-410 , ,
, .
.
. .
,
. .
, , -
.
.

: .

1. -
.

2. - , -
, .

3. , .

: , .

1.
(). -
-
;

;

2. ( -
, , , -

226
 ..) -
;

3. ;

4.
, ;

5.
;

6. ,
, -
;

7. (, ,
, ), , -
, -
;

8.
;

9.
(, , ), , ,
, ..;

10.

( , ),
;

11. -
, , -
, , -
, , , , .

12. , -
;

13.
;

227
 14. ,
;

15.
, ;

16. -
, -
,
; ;

17. -
-

, ,
() ; -
(, ) ( , -
);

18. ,
, ;

19. -
, , ,
, -
, -
;

20.
,
;

21. , -
, , , , .

22. ,
, .;

23.
:

228
 -
;

-
;

-
;

, -

, , , ;

,
;

-
.

1. , . . ., . ., 1992, 589 .
2. . . . - . . , , 1994.
3. , . . . . ., 2007, IP
Bulgaria, 349-368.
4. , . . ., . ., 2002,813 .
5. . . . . . .. .,
. ., 1987.
6. , . .., , 2012,
208.
7. C a r d u c c i , R. et al. Silibinin and acute poisoning with ''Amanita phalloides''. Minerva
Anestesiologica, 62, 1996, 5, 187-193.
8. C l a r k e 1 , S. F. J., P. I. Dargan et A. L. Jones. Naloxone in opioid poisoning: walking
the tightrope. Emerg. Med. J., 22, 2005, 612-616.

229
9. E g l i , G. et al. Nahrungsmittelvergiftungen. Schweiz. Med. Forum, 2005, 5, 494-499.
10. E n j a l b e r t , F. et al. Treatment of amatoxin poisoning: 20-year retrospective analysis.
Journal of Toxicology Clinical Toxicology, 40, 2002, 6, 715-757.
11. H e n r y , J. A. Carbon monoxide. J. Acc. Emerg. Med., 16, 1999, 91-92.
12. H r u b y , K. et al. Chemotherapy of Amanita phalloides poisoning with intravenous
silibinin. Human Toxicology, 2, 1983, 2, 183-195.
13. J a n d e r , S., J. Bischoff et B. G. Woodcock. Plasmapheresis in the treatment of Amanita
phalloides poisoning: II. A review and recommendations. Therapeutic apheresis, 4, 2000, 4,
308-312.
14. K a c i , M. et al. Mycetismus in children--report of an epidemic of poisoning. Lijecnicki
vjesnik, 112, 1990, 11-12, 369-373.
15. M e i e r - A b t , P. et H. Kupferschmidt. Dekontamination und wichtigste Antidote. Schweiz.
Med. Forum., 16, 2001, 402-405.
16. S a b e e l , A. I., J. Kurkus et T. Lindholm. Intensive hemodialysis and hemoperfusion treatment
of Amanita mushroom poisoning. Mycopathologia, 131, 1995, 2, 107-114.
17. S m o k e Inhalation and Hydrogen cyanide Poisoning. A Jemes Communications Supplement.
Sponsored by EMD Pharmaceuticals., Elsevier Inc., 2004.
18. O m i d y n i a , E. et al. Mycetismus in Hamadan, of west Iran. J. Trop. Med. Public Health., 28,
1997, 2, 438-439.
19. S p e d d i n g , R. et al. Carbon monoxide poisoning. Update, 1999, 568-571.
20. T i b b l e s , P. M. et al. Hyperbaric oxygen therapy. N. Engl. J. Med., 334, 1996, 1642-
1648.
21. V e s c o n i , S. et al. Therapy of cytotoxic mushroom intoxication. Critical Care
Medicine, 13, 1985, 5, 402-406.
22. W a l k e r , E. et A. Hay. Carbon monoxide poisoning. BMJ, 319, 1999, 1082-1083.
23. W e a v e r , L. K. Hyperbaric oxygen in carbon monoxide poisoning. BMJ, 319, 1999,
1083-1084.

230